

**REVIEW ARTICLE**

**Fibroblast growth factors and their receptors in cancer**

Jørgen WESCHE<sup>1</sup>, Kaisa HAGLUND and Ellen Margrethe HAUGSTEN

Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway and Department of Biochemistry, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Montebello, 0310 Oslo, Norway

FGFs (fibroblast growth factors) and their receptors (FGFRs) play essential roles in tightly regulating cell proliferation, survival, migration and differentiation during development and adult life. Deregulation of FGFR signalling, on the other hand, has been associated with many developmental syndromes, and with human cancer. In cancer, FGFRs have been found to become overactivated by several mechanisms, including gene amplification, chromosomal translocation and mutations. FGFR alterations are detected in a variety of human cancers, such as breast, bladder, prostate, endometrial and lung cancers, as well as haematological malignancies. Accumulating evidence indicates that FGFs and FGFRs may act in an oncogenic fashion to promote multiple steps of cancer progression by inducing

mitogenic and survival signals, as well as promoting epithelial–mesenchymal transition, invasion and tumour angiogenesis. Therapeutic strategies targeting FGFs and FGFRs in human cancer are therefore currently being explored. In the present review we will give an overview of FGF signalling, the main FGFR alterations found in human cancer to date, how they may contribute to specific cancer types and strategies for therapeutic intervention.

**Key words:** cancer, fibroblast growth factor (FGF), fibroblast growth factor receptor (FGFR), receptor tyrosine kinase, signalling, therapy.

**INTRODUCTION**

**Cancer**

Human cancers usually develop through a multi-stage process that may extend over decades. During cancer development, normal cells are progressively transformed into highly malignant cells by accumulating a number of genetic changes and acquiring a set of specific properties that have been summarized as the hallmarks of cancer [1–5]. Four of these hallmarks, self-sufficiency in growth signals, insensitivity to anti-growth signals, evading apoptosis and limitless replicative potential, contribute to uncontrolled cancer cell proliferation [1]. Malignant cancer cells also acquire the capabilities of invading the adjacent normal tissue and metastasizing to distant organs, as well as of sustained angiogenesis to access nutrients and oxygen to promote the growth of the tumour [1]. In addition to these six classical hallmarks, further hallmarks of cancer cells have been proposed, including evasion of immune surveillance [6], enhanced anabolic metabolism [5], various stress phenotypes (i.e. DNA damage, and mitotic, metabolic, proteotoxic and oxidative stresses) [4] and genomic instability [3]. Given the complexity of carcinogenesis, the mechanisms and the temporal sequence by which these features are acquired will probably vary between cancer types and subtypes [1].

Cancers may be hereditary or sporadic depending on whether the tumour-causing mutations occur in the germline or in somatic cells respectively [3]. Tumours display a tremendous complexity

and heterogeneity in the pattern of mutations, and often display mutations in multiple genes, chromosomal abnormalities and changes in gene expression [4]. The accumulation of genetic alterations leading to overactivation of growth-promoting oncogenes and/or inactivation of growth-inhibitory tumour suppressor genes is strongly linked to tumour progression [7]. It is thought that some mutations, so-called driver mutations, give cancer cells a considerable growth advantage and promote cancer cell expansion, whereas others, termed passenger mutations, do not contribute to cancer progression [8]. Increasing evidence suggests that the continued activity of one or a few driving oncogenes promote the malignant phenotype of tumours that become dependent on these oncogenes for the maintenance of the tumour hallmarks, a phenomenon called ‘oncogene addiction’ [9]. RTKs (receptor tyrosine kinases) represent an important family of genes that is commonly affected by mutations and alterations in human cancers.

**RTKs in cancer**

RTKs constitute a large family of cell-surface receptors with 58 members divided into 20 subfamilies in humans, all of which share a common overall composition with an extracellular ligand-binding region, a single-pass transmembrane domain and an intracellular tyrosine kinase domain [10]. Growth factor binding to the ligand-binding domain induces RTK activation and the initiation of intracellular signalling cascades that control vital

Abbreviations used: BCR, breakpoint cluster region; EGF, epidermal growth factor; EGFR, EGF receptor; EMS, 8p11 myeloproliferative syndrome; EMT, epithelial–mesenchymal transition; ESCRT, endosomal sorting complex required for transport; FGF, fibroblast growth factor; FGFR, FGF receptor; FKHR, forkhead in Rhabdomyosarcoma; FLRT, fibronectin-leucine-rich transmembrane protein; FRS2, FGFR substrate 2; GRB2, growth-factor-receptor-bound protein 2; HGF, hepatocyte growth factor; HSPG, heparan sulfate proteoglycan; MAPK, mitogen-activated protein kinase; MM, multiple myeloma; MMSET, MM SET domain; MT1-MMP, membrane-type 1 matrix metalloproteinase; NCAM, neural cell-adhesion molecule; NSCLC, non-small cell lung carcinoma; PAX3, paired box 3; PDGF, platelet-derived growth factor; PDGFR, PDGF receptor; PI3K, phosphoinositide 3-kinase; PIN, prostatic intraepithelial neoplasia; PKC, protein kinase C; PLC $\gamma$ , phospholipase C $\gamma$ ; RMS, Rhabdomyosarcoma; RTK, receptor tyrosine kinase; SCLC, small cell lung carcinoma; SCLL, stem cell leukaemia lymphoma syndrome; SEF, similar expression to FGF; SNP, single-nucleotide polymorphism; SPRED2, Sprouty-related enabled/vasodilator-stimulated phosphoprotein homology 1 domain-containing protein; UCC, urothelial cell carcinoma; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor.

<sup>1</sup> To whom correspondence should be addressed (email Jorgen.Wesche@rr-research.no).

cellular processes, such as cell proliferation, differentiation, migration and survival [10]. RTKs thereby play key roles in maintaining tissue homeostasis during the development and adult life of multicellular organisms [11,12]. Accumulating evidence indicates that deregulation of RTK signalling, on the other hand, is linked to the development of various human diseases, including cancer [11,13]. Mechanisms that have been implicated to contribute to aberrant RTK activation in carcinogenesis include gene amplification, chromosomal translocation, point mutation, autocrine activation and impaired receptor down-regulation [11,14–17]. Most often altered RTKs act as oncoproteins, but in certain cases RTKs may also have tumour suppressor functions (see below) [13]. Prominent examples of RTKs that have been found altered in human cancer include members of the ErbB/EGFR [EGF (epidermal growth factor) receptor], PDGFR [PDGF (platelet-derived growth factor) receptor], VEGFR [VEGF (vascular endothelial growth factor) receptor], HGF [HGF (hepatocyte growth factor) receptor]/MET and FGFR [FGF (fibroblast growth factor) receptor] families [11,16].

Aberrant RTK activation following the above alterations may promote several steps of cancer progression. Most cancers originate from epithelial tissues and the consensus view is that the majority of human sporadic cancers originate from a single progenitor cell containing somatic driver mutations that give survival and growth advantages to the cell [13]. Growth factors and their receptors have been implicated in a number of the subsequent steps of progression to a malignant cancer phenotype [13]. First, growth factors, such as EGF and IGF-1 (insulin-like growth factor-1), may participate in promoting the clonal cancer cell expansion that leads to the formation of benign lesions [13]. These cells may further undergo EMT (epithelial–mesenchymal transition), a process that involves loss of epithelial cell polarity, enhanced migratory capacity, the acquirement of a mesenchymal phenotype and secretion of proteases [18]. This is followed by degradation of the basement membrane and migration and invasion of the cells into the normal adjacent tissue, giving rise to malignant lesions [18]. A large number of oncogenes and tumour suppressors, as well as growth factors, including TGF $\beta$  (transforming growth factor  $\beta$ ), HGF, FGF and EGF, have been implicated in these processes [13,19]. Having invaded neighbouring tissues, cancer cells can gain access to and enter blood and lymphatic vessels (intravasation), followed by their transport through the circulation, lodging in capillaries in distant tissues and exit from vessels (extravasation) to penetrate into the surrounding tissues to form micrometastases, some of which may eventually grow to macroscopic metastases [20]. The growth and survival of primary and secondary tumours larger than a few millimetres in size require access to the circulation and the generation of new vessels by tumour angiogenesis [21]. VEGF, PDGF and FGF all play roles in stimulating angiogenesis [13,22]. Taken together, RTKs may thus participate in promoting several steps of carcinogenesis, including clonal cancer cell expansion, EMT, invasion and angiogenesis.

In the present review we will focus on FGFs and FGFRs, deregulation of which have been identified in a variety of human cancers. We will start by giving an overview of signalling pathways and biological processes induced by FGFs and their receptors. We will then discuss the main mechanisms by which FGFs and FGFRs have been found to be altered in human cancer, and highlight the cancer types in which FGF/FGFR alterations have been commonly found to date and how they may contribute to a malignant phenotype. We will finally discuss possibilities for therapeutic interventions of FGFs and FGFRs in treatment of human cancer.

## THE FGF SIGNALLING SYSTEM

### FGFs and FGFRs

The FGF family consists of 18 ligands that bind to four homologous high-affinity FGFRs (FGFR1–FGFR4) [12,22,23]. The FGFs are secreted polypeptidic growth factors that bind to receptors expressed at the cell surface of target cells. Most FGFs have signal sequences for secretion, except FGF1 and FGF2 that utilize a non-classical secretion pathway circumventing the ER (endoplasmic reticulum). In addition to the 18 secreted ligands that bind to cell-surface receptors, four members of the FGF family, the FHF (FGF homologous factors), are not secreted and act intracellularly [12].

The FGFRs have an overall structure similar to most RTKs [23]. They are single-pass transmembrane proteins that consist of an extracellular part that binds FGF ligands, a transmembrane domain and an intracellular tyrosine kinase domain that transmits the signal to the interior of the cell (Figure 1). The intracellular kinase domain is similar to the VEGFR and PDGFR kinases in that it has an insert, resulting in a split kinase domain. The extracellular part is composed of three Ig-like domains (I–III) with an acidic, serine-rich region between domains I and II (termed the acid box). The first Ig-like domain is, together with the acid box, thought to play a role in receptor autoinhibition [24]. Domains II and III constitute the FGF ligand-binding site. In FGFR1–3, alternative splicing in Ig-like domain III creates isoforms with different ligand-binding specificities (FGFR1 IIIb–FGFR3 IIIb and FGFR1 IIIc–FGFR3 IIIc) [12,23]. The FGFR IIIb isoforms are predominantly epithelial and the IIIc isoforms are predominantly mesenchymal, with their corresponding ligands only activating either the epithelial or mesenchymal isoforms, except FGF1 which binds all receptor isoforms [25]. Thus paracrine signalling is achieved by, for instance, epithelial cells producing ligands that only activate the corresponding mesenchymal FGFR IIIc isoforms, and vice versa.


FGFs also bind to low-affinity receptors present on most cells, the HSPGs (heparan sulfate proteoglycans) [12]. HSPGs consist of a proteoglycan core that binds two or three linear polysaccharides (heparan sulfate chains). The FGFs bind to the negatively charged polysaccharides through electrostatic interactions. HSPGs both protect the ligands from degradation and are also involved in the complex formation between the FGFs and the FGFRs. Binding of FGFs to the receptors forces the dimerization of a ternary complex consisting of FGF, FGFR and heparan sulfate (Figures 1 and 2).

### FGF signalling

The dimerization event triggers the activation of the FGFRs by bringing the intracellular kinases into close proximity, enabling them to transphosphorylate each other. Seven phosphorylation sites have been identified in FGFR1 (Tyr<sup>463</sup>, Tyr<sup>583</sup>, Tyr<sup>585</sup>, Tyr<sup>653</sup>, Tyr<sup>654</sup>, Tyr<sup>730</sup> and Tyr<sup>766</sup>) [26,27]. Some of these phosphotyrosine groups acts as docking sites for downstream signalling molecules containing SH2 (Src homology 2) domains.

One prominent example is PLC $\gamma$  (phospholipase C $\gamma$ ), which binds to a phosphotyrosine in the C-terminal tail of the activated receptors (Tyr<sup>766</sup> in FGFR1, Figure 2) [27]. PLC $\gamma$  hydrolyses PIP<sub>2</sub> (phosphatidylinositol 4,5-bisphosphate) to produce DAG (diacylglycerol) and IP<sub>3</sub> (inositol 1,4,5-triphosphate) which triggers the release of calcium and subsequent activation of PKC (protein kinase C).

The adaptor protein FRS2 (FGFR substrate 2) acts as a hub linking several signalling pathways to the activated FGFRs



**Figure 1** Complex formation between FGF, FGFR and HSPG initiates signalling

The basic structure of an FGFR is shown on the left-hand side. FGFRs are single-pass transmembrane RTKs with an extracellular part composed of three Ig-like domains (I–III), and an intracellular part containing a split tyrosine kinase domain. The complex formed by two FGFs, two heparan sulfate chains and two FGFRs causes dimerization and transphosphorylation by the kinases on several tyrosine residues in the intracellular part of the FGFRs, causing activation of downstream signalling cascades. After activation, the complex is internalized by endocytosis and transported to lysosomes for degradation. See the text for more details. An animated version of the Figure is available at <http://www.BiochemJ.org/bj/437/0199/bj4370199add.htm>.

[28]. FRS2 binds to the juxtamembrane region of the FGFR, and upon activation of the receptor it becomes phosphorylated on several tyrosine residues, creating docking sites for additional adaptor proteins. By binding to phosphorylated FRS2, the adaptor GRB2 (growth-factor-receptor-bound protein 2) recruits the Ras/MAPK (mitogen-activated protein kinase) pathway through the Ras guanine-nucleotide-exchange factor SOS (Son of sevenless) and the PI3K (phosphoinositide 3-kinase)/Akt pathway through GAB1 (GRB2-associated-binding protein 1) (Figure 2).

Many other signalling molecules have been reported to be activated by FGFRs, including RSK2 (p90 ribosomal protein S6 kinase 2), STATs (signal transducers and activators of transcription) and the non-RTK Src [12,22].

### Modulation of FGF signalling

A number of regulators are implicated in modulating the signalling output from activated FGFRs. The Sprouty proteins, for example, are important negative regulators that are induced by FGF signalling [29–31]. Sprouty proteins seem to inhibit signalling by several mechanisms. They inhibit signalling by binding to GRB2 and thereby decouple downstream signalling (Figure 2) [32].

Other proteins induced by FGF signalling, such as MKP3 (MAPK phosphatase 3), and SEF (similar expression to FGF), also act to attenuate the MAPK signalling pathway (Figure 2) [22,33–35]. In addition, the MAPKs themselves phosphorylate FRS2 on serine and threonine residues, thereby inhibiting the recruitment of GRB2 and creating a negative-feedback loop [36].


Positive regulators of FGF signalling also exist. The transmembrane protein FLRT3 (fibronectin-leucine-rich transmembrane protein 3) was first identified in *Xenopus laevis* to accentuate

MAPK signalling initiated by FGFRs [37]. Further studies in mammals have also implicated other members of the family (FLRT1 and FLRT2) to be positive regulators of FGF signalling [38].

The signal from the activated FGF–FGFR complex is efficiently terminated by internalization and degradation in lysosomes (Figure 1). The ubiquitin ligase Cbl can bind to activated FRS2 and mediate FGFR ubiquitination that acts as a signal for receptor degradation [39]. In the case of FGFRs, ubiquitination does not seem to be required for endocytosis [40]. Instead, the endocytic adaptor protein extended-synaptotagmin binds directly to FGFRs and recruits them to undergo clathrin-mediated endocytosis via adaptin-2 [41].

After endocytosis, the ubiquitinated receptors are sorted into multivesicular bodies by the ESCRT (endosomal sorting complex required for transport) machinery and are then further transported to lysosomes where they are degraded [42,43]. The four FGFRs are ubiquitinated to different extents and this seems to dictate whether they are efficiently degraded or transported back to the plasma membrane via recycling endosomes. FGFR1 is heavily ubiquitinated and is transported to lysosomes, whereas FGFR4 is only lightly ubiquitinated, inefficiently degraded and rather recycled to the cell surface, resulting in prolonged signalling from FGFR4 compared with FGFR1 [40,42]. In addition to the ESCRT proteins, a Sprouty-related protein, SPRED2 (Sprouty-related enabled/vasodilator-stimulated phosphoprotein homology 1 domain-containing protein), was also shown to direct FGFRs to lysosomes by interacting with the late endosomal protein NBR1 [neighbour of BRCA1 (breast cancer early-onset 1)]. SPRED2 thereby attenuates FGF signalling by causing degradation of the receptors in lysosomes [44].

Differential ligand binding can also dictate the routing of FGFRs as shown for FGFR2b [KGFR (keratinocyte growth



**Figure 2** Intracellular signalling pathways downstream of FGFRs

After ligand-induced FGFR activation, several downstream signalling cascades are initiated. Two central players, FRS2 and PLC $\gamma$  (in blue) bind directly to the receptors. FRS2 is constitutively associated with the receptor, and upon activation of the receptor kinase, it is phosphorylated on several tyrosine residues which, in turn, recruit two important signalling pathways, the Ras/MAPK and PI3K/Akt pathways. PLC $\gamma$  binds to a phosphotyrosine in the C-terminal tail of FGFRs. PLC $\gamma$  recruitment culminates in the activation of PKC. Several negative regulators are also associated with FGF signalling (in red). Soluble heparin (in orange), a highly sulfated polysaccharide, can take the place of HSPG in the FGF complex and is often used experimentally to increase FGF signalling. See the text for more details.

factor receptor)]. The binding of FGF7 to FGFR2b causes efficient ubiquitination, resulting in degradation of the complex in lysosomes. Another FGFR2b ligand, FGF10, however, does not induce receptor ubiquitination, and the complex is transported to recycling endosomes causing prolonged signalling [45].

Yet another interesting example of differential trafficking of FGFRs is the re-routing of FGFR1 after binding to NCAM (neural cell-adhesion molecule). The interaction of FGFR1 with NCAM causes recycling and sustained signalling, which is important for the stimulation of cell migration [46].

### Biological responses

FGF signalling pathways are implicated in a multitude of biological processes. They stimulate proliferation, act as pro-survival/anti-apoptotic signals and stimulate cell migration in many cell types [12]. Proliferation signals are mainly transmitted through the MAPK signalling cascade and anti-apoptotic signals are through the PI3K/Akt pathway. However, there is considerable cross-talk between the signalling pathways, for example, during FGF-induced cell migration, both MAPK and PI3K seem to be required.

FGFs are crucial during development where they have been shown to be key molecules in organogenesis [22,47]. FGF signalling is implicated in the formation of the heart, the lungs, the limbs and the nervous system, and also plays an important role in mammary and prostate gland development. During early development, induction of the mesoderm is orchestrated through FGF-dependent epithelial–mesenchymal communication.

In addition, FGF signalling plays a role in the formation of new blood vessels, the process of angiogenesis, by influencing other key signalling molecules such as HGF and VEGF [48]. Interestingly, FGFs, and in particular FGF2, have been shown to support the undifferentiated self-renewal of human embryonic

stem cells and are routinely used to cultivate such cells in the laboratory [49].


It is evident that FGFs and FGFRs constitute a robust signalling system orchestrating many important signalling pathways and biological responses, and efficient negative regulation is crucial. We will in the next sections see how out of control FGF signalling can cause disease.

### MECHANISMS FOR DEREGULATION OF FGF SIGNALLING IN CANCER

As discussed above, FGFs and FGFRs constitute a highly complex signalling system, and since signals from these receptors regulate many key processes, they must be kept tightly regulated. However, FGF signalling is often subverted to cause constitutive signalling without proper regulation in cancer [14,50–56]. There are several ways by which the FGF signalling network can be deregulated in human cancers, and we will in the following sections discuss common ways that lead to aberrant signalling from FGFs and FGFRs (Figure 3).

#### Mutations

FGF signalling is crucial during development, and mutated FGFRs have been found to be the cause of several developmental syndromes [28,57]. Prominent examples include the germline gain-of-function mutations often found in human skeletal dysplasia. For instance, in achondroplasia, a mutation in the transmembrane helix of FGFR3 (G380R) promotes dimerization and subsequent activation of the tyrosine kinase domain [58]. In the lethal skeletal disorder thanatophoric dysplasia, single mutations generating a new cysteine residue (S249C or Y373C) in the extracellular part of the receptors cause the formation of a disulfide bond, linking two individual receptors [59]. Thus an



**Figure 3** Possible mechanisms for deregulated FGF signalling

The FGFR can be activated independently of ligand stimulation by several mechanisms. Some point mutations (in red) can lead to increased receptor dimerization, whereas other mutations in the kinase domain can result in constitutively active kinases. FGFR overexpression leading to excessive signalling may be caused by gene amplification or aberrant transcriptional regulation. Chromosomal translocation can result in fusion of the kinase domain of an FGFR to a dimerization domain from another protein leading to constitutive kinase activation. In other cases, aberrant signalling can be caused by autocrine loops when the same cell produces both a ligand and a corresponding FGFR, or paracrine loops if the cell produces FGFRs with altered ligand specificity towards FGFs (in blue) secreted by surrounding cells. See the text for more details.

intermolecular bond forces dimerization in the absence of ligand, resulting in ligand-independent constitutive signalling.

Interestingly, the same mutations discovered to be the cause of many developmental disorders are also found mutated in tumour cells (Table 1). The mutations found in achondroplasia and thanatophoric dysplasia, which cause dimerization and thereby constitutive activation of FGFR3, are also frequently found in bladder cancer [60]. Yet other mutations in FGFR2 that cause dimer formation are implicated in craniosynostosis syndromes and have also been found in endometrial cancers [55,61].

A mutation that promotes dimerization is just one mechanism that can increase ligand-independent signalling from FGFRs. Other mutations located to the kinase domain of FGFRs can change the conformation of the domain to cause permanently active kinases. Mutations in the kinase domain of FGFR4 have been found in the childhood sarcoma RMS (Rhabdomyosarcoma), and these mutations were shown to cause autophosphorylation and constitutive signalling [50].

Some mutations in FGFRs identified in human cancer have also been shown to cause loss-of-function suggesting that, in certain circumstances, FGFRs can act as tumour suppressors [62].

The majority of FGF ligand mutations described in human disease are germline loss-of-function mutations. Examples include the FGF3 mutation that causes deafness, mutations in FGF8 that result in Kallmann syndrome and FGF10 mutations that have been described in LADD (Lacrimo-Auriculo-Dento-Digital)

syndrome. In cancer, however, the prevalence of mutations in FGF ligands is rare and the consequences of such mutations are not clear. The only mutations described in cancer are, to our knowledge, the somatic mutations in FGF9 found in colorectal and endometrial cancers [63]. The mutations were predicted to result in loss-of-function and it is not known whether these mutations participate in tumour formation.

### SNPs (single-nucleotide polymorphisms)

Certain germline SNPs have been identified in FGFRs and are believed to modulate the malignant phenotype in some cancer types. The FGFR4 G388R SNP has been shown to confer a more aggressive behaviour and increased metastatic potential in several forms of cancer (e.g. breast, lung, skin, colon and prostate cancers) [64–68]. The molecular mechanism by which FGFR4 G388R promotes tumour progression and metastasis is not fully understood, but it has been reported that FGFR4 G388R exhibits sustained signalling compared with wild-type FGFR4 due to impaired lysosomal degradation [69]. Recently, it was also shown that FGFR4 G388R forms a complex with MT1-MMP (membrane-type 1 matrix metalloproteinase) and thereby decreases MT1-MMP lysosomal degradation leading to increased invasion [70].

Several SNPs within intron 2 in FGFR2 have been shown to be associated with an increased risk of breast cancer. It has been proposed that these SNPs alter binding affinity for

**Table 1** FGFR aberrations identified in human cancer

The Table lists FGFR mutations, amplifications and translocations that have been associated with altered kinase activity. Included in the Table are only the aberrations identified in human tumour samples. For references and a more complete list, see Supplementary Tables S1–S3 (at <http://www.BiochemJ.org/bj/437/bj4370199add.htm>). The FGFR3 IIIb isoform is two amino acids longer than FGFR3 IIIc, and in order to avoid confusion, numberings according to both the FGFR3 IIIb and IIIc isoforms are indicated. FGFR1 IIIc (GenBank® accession number NM\_023110), FGFR2 IIIc (GenBank® accession number NP\_000132), FGFR3 IIIc (GenBank® accession number NP\_000133), FGFR4 (GenBank® accession number X57205). ACH, achondroplasia; amp, amplification; AN, acanthosis nigricans; AS, Apert syndrome; CR, craniosynostosis; CS, Crouzon syndrome; HCH, hypochondroplasia; PS, Pfeiffer syndrome; SADDAN, severe achondroplasia with developmental delay and acanthosis nigricans; TDI/II, Thanatophoric Dysplasia I/II; trans, translocation.

Cancer	Receptor	Aberration	Association with other syndromes	Molecular consequence
Breast	FGFR1	8p11-12 amp	Not known	Amplification of FGFR1
Bladder	FGFR3	R248C	TDI	Enhanced kinase activity
	FGFR3	S249C	TDI	Enhanced kinase activity
	FGFR3	G370/372C	TDI	Enhanced kinase activity
	FGFR3	S371/373C	TDI	Enhanced kinase activity
	FGFR3	Y373/375C	TDI	Enhanced kinase activity
	FGFR3	G380/382R	ACH	Enhanced kinase activity
	FGFR3	A391/393E	CS	Enhanced kinase activity
	FGFR3	K650/652E/Q/M/T	TDI, TDII, HCH, SADDAN, AN	Enhanced kinase activity
	FGFR3	S249C	TDI	Enhanced kinase activity
Prostate	FGFR3	A391E	CS	Enhanced kinase activity
Endometrial	FGFR2	S252W	AS	Alter ligand specificity
	FGFR2	P253R	AS	Alter ligand specificity
	FGFR2	N549K	Not known	Enhanced kinase activity
	FGFR2	K659N	CR	Enhanced kinase activity
Lung	FGFR1	8p12 amp	Not known	Amplification of FGFR1
	FGFR2	W290C	PS	Not known*
RMS	FGFR4	N535K	Not known	Enhanced kinase activity
	FGFR4	V550E	Not known	Enhanced kinase activity
MM	FGFR3	t(4:14) trans	Not known	Overexpression of FGFR3
	FGFR3	R248C	TDI	Enhanced kinase activity
	FGFR3	K650/652M	TDI, SADDAN	Enhanced kinase activity
Brain	FGFR1	N546K	Not known	Enhanced kinase activity
	FGFR1	K656E	Not known	Enhanced kinase activity
Head and neck	FGFR3	R248C	TDI	Enhanced kinase activity
	FGFR3	S249C	TDI	Enhanced kinase activity
	FGFR3	G697C	Not known	Enhanced kinase activity
Melanoma	FGFR2	I642V	Not known	Reduced kinase activity
EMS	FGFR1	8p11-12 trans	Not known	Constitutively active FGFR1-fusion proteins

\* FGFR2 W290G forms ligand-independent dimers

transcription factors causing an increase in FGFR2 expression [71,72].

### Fusion proteins

Potent aberrant FGF signalling can be the result of chromosomal translocations in which protein domains causing dimerization are fused to the kinase domain of an FGFR (Figure 3). These intracellularly localized fusion proteins are permanently dimerized in the absence of ligand, resulting in continuous signalling. As these fusion proteins are not expressed at the cell surface, but rather reside in the cytosol, they escape the normal down-regulation routes operating for wild-type receptors. They are neither degraded in lysosomes nor inhibited by some of the feedback inhibitors, giving rise to constitutively active receptor kinases with little negative regulation. They are therefore particularly potent oncogenes that can drive proliferation of cancer cells. Most FGFR-fusion proteins have been found in EMS (8p11 myeloproliferative syndrome), also called SCLL (stem cell leukaemia lymphoma syndrome), where the kinase domain of FGFR1 is fused to one of several different N-terminal dimerization domains [e.g. ZNF198, BCR (breakpoint cluster region), FOP2] (Supplementary Table S3 at <http://www.BiochemJ.org/bj/437/bj4370199add.htm>) [73].

### Differential expression

Ligand-independent signalling can also occur from overexpressed FGFRs. When overexpressed, individual FGFRs can interact and phosphorylate each other, probably because of the local crowding of receptors at the cell surface (Figure 3). Overexpression is often caused by amplification of distinct pieces of the chromosome resulting in multiple copies of the gene. In human breast cancer, ~10% of the patients harbour the 8p11-12 amplicon that contains *FGFR1* and, in most cases, results in overexpression of FGFR1 [74–76]. Aberrant transcriptional regulation can also lead to increased levels of the receptors.

It should also be noted that, in some tumours, FGFR expression has been found to be down-regulated, indicating that in certain cases they may act as tumour suppressors [22]. Expression of FGFs or FGFRs out-of-context can lead to autocrine or paracrine signalling loops (Figure 3). For instance, if an FGFR-expressing cell also overexpresses its matching ligand, an autocrine loop can be established and the cancer cell becomes self-sufficient in growth signals [22].

If the cancer cells overexpress an FGFR with altered ligand-binding specificity, FGFs secreted from neighbouring cells can stimulate the cancer cells, creating a paracrine loop. For instance, alternative splicing of the third Ig-like domain in FGFR1–3 can switch the binding affinity of the receptor towards FGFs found in

the surrounding milieu, creating an aberrant paracrine signalling loop (Figure 3).

### Impaired down-regulation of FGF signalling

Increased levels of FGFRs on the cell surface can also be the result of impaired down-regulation. After binding, the ligand–receptor complex is normally endocytosed and transported to lysosomes for degradation (Figure 1). Defective internalization will result in higher levels of receptor on the cell surface and prolonged signalling. Mutations in any protein involved in the internalization of FGFRs could thus potentially increase FGF signalling. Alterations in proteins involved in the endocytic machinery have been found in many cancers [15]. For example, Cbl, the ubiquitin ligase responsible for the proper down-regulation of many RTKs, has been found mutated in AML (acute myeloid leukaemia), causing an accumulation of the RTK FLT3 (FMS-like tyrosine kinase 3). It would be interesting to investigate whether similar mechanisms operate for FGFRs in certain cancers.

There is also the possibility that alterations in the FGFRs themselves can prevent efficient internalization and degradation of the receptors. For instance, the FGFR3 G380R mutation found in achondroplasia and bladder cancer promotes dimerization, but in addition also increases recycling of the receptor, thereby avoiding efficient receptor degradation and resulting in prolonged signalling [77].

A splice variant of FGFR2 found in several cancer cell lines results in a shortened C-terminus [78]. The deleted C-terminal tail contains an endocytic motif, and it was shown that the transforming capacity of the FGFR2 variant was partly due to inefficient down-regulation, causing increased receptor levels at the cell surface and thus enhanced signalling capacity [78].

Deregulation of negative regulators of FGF signalling has also been suggested to be involved in oncogenicity [22]. For instance, the expression of SEF and Sprouty is decreased in prostate cancer and could cause excessive signalling by relieving an inhibitory brake [79,80].

We will now give an overview of the most common types of human cancer in which FGF and FGFR alterations have been found and how they may contribute to cancer progression.

## THE ROLES OF FGFS AND FGFRS IN CANCER

### Breast cancer

FGFRs and several of the FGFs play a critical role in regulating normal mammary gland development and tissue homeostasis. In particular, FGFR2 IIIb and FGF10 are required for embryonic mammary gland development, and for survival and proliferation of epithelial cells during postnatal development [81–83]. Ectopic expression of a number of FGF/FGFR family members has been reported in human breast cancer. The most common alteration involves amplification of FGFR1. As mentioned previously, amplification of the chromosomal region 8p11-12, where FGFR1 is located, appears in approximately 10% of human breast cancers and is associated with poor prognosis (Table 1) [74–76]. Studies from breast cancer cell lines and mouse models support a role for FGFR1 signalling in mammary carcinogenesis. Activation of FGFR1 in mouse or human mammary cell lines resulted in increased cell proliferation, survival and invasion [84,85], confirming the potential oncogenic nature of FGFR1 signalling. Moreover, expression and constitutive activation of

FGFR1 in the mouse mammary epithelium induced proliferation and invasive lesions [86]. Recently it was also reported that FGFR1 amplification drives resistance to endocrine therapy [53]. Taken together, there is strong evidence that FGFR1 amplification plays a role in breast carcinogenesis. It is, however, worth mentioning that FGFR1 is not always overexpressed when the 8p11-12 region is amplified, and genes other than FGFR1 in the 8p11-12 amplicon are also likely to contribute to carcinogenesis [87–89].

FGFR2 has also been implicated in some cases of breast cancer. Amplification of FGFR2 has been described in a subgroup of triple-negative breast tumours, which are aggressive breast tumours negative for the oestrogen receptor, progesterone receptor and HER2 (human EGFR 2)/ErbB2 [90]. Cell lines derived from these tumours showed constitutive activation of FGFR2, and were sensitive to FGFR2 inhibition using a specific FGFR inhibitor (PD173074) and to RNAi silencing. Triple-negative breast cancers are not efficiently treated with current targeted therapies [91], and FGFR2 might therefore be a novel therapeutic target in the subset of triple-negative breast tumours harbouring *FGFR2* gene amplification.

Ectopic expression of FGFR4 has also been reported in human breast cancer [92] and has been associated with resistance to chemotherapy in breast cancer cell lines [93]. In an experimental approach to identify signalling pathways that define chemoresistance in cancer, a breast cancer cell line was treated with doxorubicin and gene expression levels of surviving cells were analysed. Isolated clones of surviving cells showed up-regulated expression of FGFR4, and interfering with FGFR4 (using an antagonistic FGFR4 antibody) enhanced chemosensitivity in FGFR4-expressing breast cancer cells [93]. These findings implicate FGFR4 as an important factor in breast-cancer-cell resistance during chemotherapy, and FGFR4 may be a potential therapeutic target in these cells.

High expression of FGFs has been reported in human breast cancer. Amplification of FGF3 occurs in approximately 15–20% of human breast cancers [94–96] and was shown to correlate with increased invasiveness in node-negative breast carcinoma. FGF8 is highly expressed in human breast cancer as opposed to normal breast tissue [97], and overexpression of FGF8b in breast cancer cells increased cell growth in culture and led to tumour formation and neovascularisation when injected into nude mice [98]. Moreover, a neutralizing antibody against FGF8 displays potent anti-tumour activity against mammary mouse tumours [99]. Also, FGF10 is highly expressed in a subset of human breast carcinomas [100]. It has been shown that subcutaneous injection of FGF10-expressing breast cancer cells into mice resulted in malignant tumours, indicating a role for FGF10 in mammary tumourigenesis [100].

Taken together, there is good evidence supporting a role for several FGF/FGFR family members in human breast cancer.

### Bladder cancer

The most common form of bladder cancer, UCC (urothelial cell carcinoma), begins in the urothelial lining of the bladder wall [101] and arises and progresses along two distinct pathways [102]. One pathway, accounting for 70–80% of UCC, is characterized by low-grade and non-invasive tumours. These tumours harbour frequent mutations in FGFR3 (approximately 70%), indicating a crucial role of FGFR3 in this tumorigenic pathway [60]. The other pathway, accounting for 20–30% of UCC, is characterized by high-grade invasive tumours and has frequent defects in the *p53* gene. Approximately 70% of the low-grade non-invasive

tumours will recur, but only approximately 15% will proceed into invasive tumours [101].

Many of the FGFR3 mutations that have been identified in human UCC result in an amino acid substitution in the extracellular, transmembrane and/or cytoplasmic domain, and are identical with activating mutations associated with human skeletal disorders [60,103,104]. The most common FGFR3 mutations in UCC (R248C, S249C, G370/372C and Y373/375C) lead to ligand-independent dimerization (Table 1). Several mutations in the kinase domain of FGFR3, leading to enhanced kinase activity, are also found in bladder cancer [103,105,106].

The presence of FGFR3 mutations in a substantial group of UCC suggests FGFR3 as a potential therapeutic target in low-grade non-invasive tumours. Several studies indicate an oncogenic role for mutationally activated FGFR3 in UCC. Knockdown of mutated FGFR3 or inhibition of FGFR3 using antibody-based targeting or specific FGFR inhibitors, such as SU5402 or PD173074 in UCC cell lines reduced their tumour properties [107–110]. Moreover, inhibition of mutated FGFR3 (using a specific FGFR inhibitor, PD173074, or a monoclonal antibody targeting FGFR3, R3Mab) in mouse xenografts decreased tumour growth [108,109,111]. These studies indicate that FGFR3 plays an important role in bladder cancer growth and thus could be considered an attractive candidate for targeted therapy.

The high recurrence rate (60–80%) of low-grade non-invasive UCC requires long-term expensive patient monitoring [112]. New urinary tumour markers may increase the accuracy of predicting tumour recurrence and lower the cost of long-term patient monitoring. Recent data suggest that detection of FGFR3 mutations in voided urine from patients with a low-grade FGFR3 mutant primary tumour indicates recurrence [113,114]. Thus identification of FGFR3 mutations is not only a potential biomarker for bladder cancer diagnosis and prognosis, but could also indicate tumour recurrence.

Elevated levels of FGF/FGFR family members in bladder cancer have been reported for FGFR3, as well as for FGFR1, FGFR2 and FGF2 [106,115,116]. Decreased levels of FGFR2 have also been reported in a subset of human UCC [117], and a role for FGFR2 in human bladder cancer is unclear. An experimental study in urothelial cell lines has suggested a role for FGFR1 in human bladder cancer [116]. Tomlinson et al. [116] reported that expression of FGFR1 in normal urothelial cells induced increased cell proliferation and survival, and that subcutaneous injection of FGFR1-knockdown cells into nude mice led to reduced tumour growth compared with control cells. These data indicate that FGFR1 displays tumorigenic properties when overexpressed in urothelial cells and may represent a potential therapeutic target in some cases of urothelial carcinoma.

### Prostate cancer

The interplay between mesenchymal/stromal cells and epithelial cells in the prostate gland play important roles during prostate gland development, but also help to maintain tissue homeostasis in the adult. Stromal–epithelial cross-talk is also integral to prostate cancer progression and metastasis [118]. Normal prostate stromal cells produce several FGFs, including FGF2, FGF7 and FGF9, whereas epithelial cells express corresponding FGFRs, and FGF/FGFR family members act as mediators of communication between the epithelium and the stroma [119].

In prostate cancer several FGFs, including FGF1, FGF2, FGF6, FGF7, FGF8 and FGF9, are up-regulated [119,120]. Stromal up-regulation and release of FGF2 has a tumour-promoting effect on neighbouring epithelial cells [121]. Overexpression of FGF10

in the stromal compartment of the murine prostate resulted in epithelial transformation and the formation of well-differentiated prostate carcinomas [122]. These data indicate an important role for FGFs produced in the tumour microenvironment in cancer progression.

Ectopic expression of FGFs in epithelial cells might also disturb the stromal–epithelial cross-talk by initiating autocrine signalling in the epithelium which can eventually lead to tumorigenesis. High expression of FGF8 in malignant prostate epithelium has been associated with decreased patient survival [123], and transgenic mice overexpressing FGF8 in prostate epithelial cells developed PINs (prostatic intraepithelial neoplasias) [124,125]. In a murine model for bone metastasis, intratibial inoculations of prostate cells expressing FGF8 increased tumour growth [126]. This indicates a role for FGF8 in prostate cancer metastasis. Interestingly, a neutralizing antibody against FGF8 displays potent anti-tumour activity against prostate tumours in mouse models [127] and might be considered as a candidate for therapeutic treatment of cancers that are dependent on FGF8 signalling for growth and survival. Previously it was also suggested that FGF9 is involved in bone metastasis in prostate cancer [128].

Overexpression of FGFRs in the prostate epithelium can also lead to autocrine signalling and disturb the stromal–epithelial communication. FGFR1 is frequently overexpressed in prostate cancer [129,130], and conditional activation of FGFR1 in prostate epithelial cells in a mouse model led to EMT and induction of adenocarcinomas [131]. Moreover, deactivation of FGFR1 during early stages of cancer progression led to regression, indicating that FGFR1 is necessary for both maintenance and progression of PINs. On the other hand, inhibition of FGFR1 later in cancer progression, reduced proliferation and progression of adenocarcinoma, but did not lead to regression. The differences in responsiveness to FGFR1 inhibition seem to depend on tumour stage and indicate a ‘susceptibility window’ for targeting FGFR1 in prostate cancer.

Although not entirely clear, taken together, the data indicate a potential role for FGF signalling in prostate cancer development.

### Endometrial cancer

Previously, mutations in FGFR2 have been identified in approximately 10% of human endometrial carcinomas (Table 1) [55,61,132]. Many of the mutations identified were identical with the germline-activating mutations in FGFR2 and FGFR3 that cause skeletal disorders and can result in enhanced activation through both ligand-dependent and ligand-independent mechanisms.

The importance of the mutations of FGFR2 identified in endometrial cancer has been investigated in endometrial cancer cell lines. In endometrial cell lines bearing N549K or K659N mutations, treatment with an FGFR inhibitor (PD173074) or knockdown of FGFR2 blocked cell proliferation and survival [55,133]. These data suggest that activation of FGFR2 plays a role in endometrial carcinogenesis and implicate FGFR2 as a potential therapeutic molecular target in the treatment of endometrial cancer.

### Lung cancer

The two main types of lung cancer are SCLC (small cell lung carcinoma) and NSCLC (non-small cell lung carcinoma). A role for FGF/FGFR family members has been indicated in both types of lung cancer.



Paracrine signalling between epithelial cells expressing FGFR2 IIIb and mesenchymal cells expressing its ligands, FGF7 and FGF10, is critical to normal lung development and tissue homeostasis [134,135]. Gene expression array data obtained from a panel of NSCLC cell lines demonstrated frequent co-expression of distinct FGFs and FGFRs, suggesting that an FGFR-dependent autocrine signalling pathway may operate in a significant fraction of NSCLCs [136]. Moreover, studies employing silencing of FGF2 and a pharmacological tyrosine kinase inhibitor (RO4383596) which also targets FGFR, indicated a functional role for an FGFR autocrine signalling pathway in NSCLC cell lines [136].

Recently, frequent amplification of FGFR1 was identified in human squamous cell lung cancer, the most common type of NSCLC [56]. Treatment of FGFR1-amplified lung cancer cell lines with the specific inhibitor (PD173074) resulted in growth inhibition and apoptosis. The PD173074-mediated cytotoxic effect could be rescued by ectopic expression of a PD173074-resistant FGFR1 mutant. Moreover, treatment with PD173074 resulted in tumour shrinkage in mice engrafted with FGFR1-amplified cells. These data suggest that FGFR1 may be a potential therapeutic option in this group of patients [137].

High copy number gain of the *FGFR1* gene has also been identified in SCLC [138]. Also, FGF2 has been suggested to play an important role in SCLC, in which high levels of serum FGF2 are associated with a poor prognosis [139]. Moreover, FGF2 induces proliferation and chemoresistance in SCLC cells [140,141]. Both of these effects could be blocked by using a specific FGFR inhibitor (PD173074) [142]. It has been shown that FGF2 up-regulates expression of anti-apoptotic proteins and thereby mediates a cytoprotective effect in SCLC [141,143,144]. Oral administration of the FGFR inhibitor in SCLC xenograft mouse models impaired tumour growth, reduced intra-tumour proliferation and increased apoptosis [142]. The data imply FGF/FGFR family members as potential therapeutic targets in SCLC.

In addition, somatic mutations in FGFR1, FGFR2 and FGFR4 have been identified in lung carcinomas [14,52,145]. One of the mutations identified in FGFR2 (W290C) may confer gain-of-function and is also associated with Pfeiffer syndrome, a skeletal disorder resulting in premature fusion of the sutures of the skull and deformity of the skull [146]. A similar mutation (FGFR2 W290G) has been demonstrated to result in ligand-independent receptor dimerization and constitutive kinase activity (Table 1) [147]. In a large screen aimed to identify somatic mutations in lung adenocarcinoma, FGFR4 was identified as one of the genes that is mutated at significantly high frequency and might be involved in carcinogenesis [52]. Taken together, the above data suggest that deregulated FGF/FGFR signalling may contribute to lung carcinogenesis.

## RMS

RMS is a cancer originating from skeletal muscle and is the most frequent soft tissue sarcoma in children [148]. Recently, several mutations in FGFR4 were identified in 7–8% of RMS tumours [50]. Many of these are clustered in the kinase domain of the receptor and at least two of them, N535K and V550E, increased autophosphorylation of the receptor (Table 1) [50]. The mutants promoted proliferation and metastatic potential when expressed in an RMS cell line [50].

High expression of FGFR4 has also been associated with advanced stage and poor survival in RMS [50,149,150]. Chromosomal translocation is common in alveolar RMS, a

subtype of RMS. One of the most common translocations leads to expression of the fusion protein PAX3 (paired box 3)–FKHR (forkhead in RMS). Recently it was reported that PAX3–FKHR acts as a strong FGFR4 expression enhancer [151]. Knockdown of FGFR4 in RMS cell lines overexpressing FGFR4 reduced cell proliferation [50]. Moreover, FGFR4 knockdown in a human RMS cell line transplanted into mice gave rise to reduced tumour growth and metastasis [50]. Taken together, these data indicate a role for FGFR4 in RMS tumorigenesis. Also, FGFR1 and FGFR2 have been reported to be overexpressed in RMS [152–154], and it has also been reported that FGFR3-positive RMS cells are more tumorigenic than FGFR3-negative cells [155].

## MM (multiple myeloma)

MM is a plasma cell malignancy that is characterized by accumulation of clonal plasma cells in bones and bone marrow where they cause bone lesions and interfere with the production of normal blood cells. Approximately 15–20% of patients suffering from MM overexpress FGFR3 as a consequence of the t(4;14)(p16.3;q32) translocation (Table 1) [156–158]. The chromosomal translocation brings FGFR3 under the influence of a strong IgH enhancer region leading to FGFR3 overexpression. It should be noted that the t(4;14) translocation in MM also results in ectopic expression of MMSET (MM SET domain) and, although ectopic expression of MMSET is found in all t(4;14) MM patients, approximately 75% of the t(4;14)-positive patients overexpress FGFR3 [158]. Moreover, carrying the t(4;14) translocation has been associated with poor prognosis irrespective of FGFR3 expression [159]. Therefore the role for FGFR3 in MM is not entirely clear.

However, experiments in MM cell lines and MM mouse models have demonstrated an oncogenic potential of FGFR3. Overexpression of FGFR3 enhanced MM cell proliferation and survival [160]. Also, inhibition of FGFR3, using highly specific antibody-targeting of FGFR3, reduced tumour growth in t(4;14)-positive MM mouse models [108,161]. A fraction of MM patients also harbour activating mutations in FGFR3, identical with those found in skeletal disorders and bladder cancer [162–164]. The activating mutations include R248C, Y373/375C, G380/G382R, G382/384D and K650/652E (Table 1 and Supplementary Table S2 at <http://www.BiochemJ.org/bj/437/bj4370199add.htm>).

Since FGFR3 is frequently overexpressed and/or mutated in MM and has been recognized as a potent oncogene, it is an attractive target for novel drug development. Several new FGFR3-targeting inhibitors/antibodies have been developed [108,161,165,166] and might prove useful for FGFR3 inhibition alone or in combination with other inhibitors in the subset of MM patients with t(4;14) FGFR3 overexpression.

## EMS

EMS/SCLL is a rare but aggressive neoplasm with a high rate of progression into acute leukaemia [73]. At the molecular level, the disorder is associated with chromosomal translocations involving the FGFR1 gene on chromosome 8p11-12, resulting in constitutively active FGFR kinase-fusion proteins (Figure 3 and Table 1, and Supplementary Table S3). The first translocation identified, and the most common, is a disruption and recombination of the *ZNF198* gene with the *FGFR1* gene. This translocation creates a chimaeric protein composed of the proline-rich zinc-finger motif of ZNF198 and the tyrosine kinase domain of FGFR1, resulting in constitutive dimerization and activation of the FGFR1 tyrosine kinase [167]. Other FGFR1-fusion partners

include FOP (FGFR1OP1), CEP110 (centriolin), BCR, TRIM24 (Tripartite motif-containing 24), FGFR1OP2, LRRFIP1 (leucine-rich repeat flightless-interacting protein 1), MYO18A (myosin-XVIIIa), CPSF6 (cleavage and polyadenylation specificity factor subunit 6), HERV-K (human endogenous retrovirus K) and CUX1 (cut-like homoeobox 1) [73,168].

Some of the FGFR1 kinase-fusion proteins can transform cell lines and induce SCLL or chronic myelogenous leukaemia-like diseases in mice [169–173]. Moreover, in a murine model of ZNF198–FGFR1-induced myeloproliferative disorder, treatment with a multi-tyrosine kinase inhibitor (PKC412) resulted in prolonged survival [171], and administration of the tyrosine kinase inhibitor to a patient with SCLL was beneficial, although not sufficient [171]. It has also been reported that growth of ZNF198–FGFR1-, FGFR1OP2–FGFR1- or BCR–FGFR1-expressing cell lines is blocked by FGFR inhibition, and treatment of FGFR1OP2–FGFR1-positive cells with multi-targeted tyrosine kinase inhibitors or siRNA (small interfering RNA) against FGFR1 resulted in apoptosis [171,173–176]. Although activation of FGFR1 appears to be the critical event in oncogenesis of EMS, it has also been suggested that the fusion partners of FGFR1 might play a role [177].

### Other types of cancer

Several additional examples of aberrant FGFR signalling in human cancers are described in the literature. Elevated levels of FGF/FGFR family members have been described in many human cancers, such as brain cancer, head and neck cancer, gastric cancer and ovarian cancer, as well as in osteosarcoma [150,178–181]. Mutated forms of FGFRs have been identified in malignancies such as brain cancer, head and neck cancer, stomach cancer and colon cancer [182–184]. Interestingly, loss-of-function mutations have been identified in FGFR2 in melanoma (Table 1) [62]. In an attempt to collect a complete up-to-date list of the reported alterations in FGFR expression in human cancers, an extensive literature search was performed and is provided with references in Supplementary Tables S1–S3 (at <http://www.BiochemJ.org/bj/437/bj4370199add.htm>). Some of the alterations found to date are frequently reported, whereas others are more rarely reported. Moreover, some reports are based on large comprehensive studies with a large number of patient samples and/or cell lines analysed, whereas others are more restricted. Alterations that are frequently reported and/or described in large studies are often regarded as the most significant. However, less frequently reported and less studied alterations might still be of significance. Note that the studies included in the Supplementary Tables are not filtered for quality or validity, and are meant as a work of reference.

### STRATEGIES FOR THERAPY

On the basis of the involvement of FGF/FGFR family members in multiple steps of cancer development and their deregulation in a variety of human cancers as described above, several therapeutic strategies aiming at interfering with FGFs or FGFR activity are being developed, including (i) small-molecule tyrosine kinase inhibitors, (ii) monoclonal antibodies and (iii) FGF ligand traps.

#### Small-molecule tyrosine kinase inhibitors targeting FGFRs

Small-molecule tyrosine kinase inhibitors inhibit the receptor kinase activity by targeting the ATP-binding site of the

intracellular tyrosine kinase domain [185]. Such inhibitors have been successfully used for therapy to target a number of different RTKs in cancer [11,13]. In the case of FGFRs, tyrosine kinase inhibitors would be relevant therapeutics for the treatment of subsets of cancers overexpressing FGFRs (e.g. breast cancer and MM), displaying activating FGFR mutations (e.g. bladder or endometrial cancers), or expressing chimaeric fusion proteins of dimerization domains fused to FGFR kinase domains (e.g. EMS) (see discussion above). Small-molecule tyrosine kinase inhibitors targeting FGFRs are currently in early phases of clinical trials (e.g. TKI258, E3810, E7080, BIBF1120, Masitinib) (<http://ClinicalTrials.gov>) [12,22,186]. Most of these inhibitors show broad specificity and target not only FGFRs, but also PDGFRs and/or VEGFRs due to high structural similarity of their kinase domains [12,22,186]. Although inhibition of several RTKs may increase the effectiveness of the treatment by interference with redundant pathways for particular cancer types, simultaneous targeting of several kinases may be associated with increased side effects. Efforts to develop more specific FGFR inhibitors are underway.

FGFR-specific tyrosine kinase inhibitors have shown promising results in interfering with FGFRs in cancer cells and mouse models. Widely used in the laboratory are the two specific FGFR kinase inhibitors SU5402 and PD173074. It should be noted that although PD173074 is widely accepted as a specific FGFR inhibitor, the use of slightly higher concentrations will also lead to VEGFR kinase inhibition [187,188]. Both inhibitors show potent anti-tumour activity in cancer cell lines and mouse models with FGFR alterations (see above), thus suggesting a potential use of small-molecule tyrosine kinase inhibitors to target FGFRs in cancer therapy. Despite their specificity against FGFRs and promising results in the laboratory, neither of these compounds has a high probability to be successfully used in the clinic owing to toxicity issues [186]. Other new specific FGFR kinase inhibitors are under development. One example is AZD4547 that is going to be tested in Phase II clinical trials for the treatment of breast cancer with FGFR1 overexpression (<http://ClinicalTrials.gov>). BGJ398, another example, is going to be tested in Phase I clinical trials in patients with advanced solid malignancies with FGFR amplifications or mutations (<http://ClinicalTrials.gov>).

The broad expression of FGFRs throughout the body and the importance of the FGFRs in various physiological processes, as well as the high degree of homology between the kinase domains of FGFRs, have to be considered in the development and application of FGFR tyrosine kinase inhibitors for cancer treatment. Certain toxicity issues and side effects, such as, for example, tissue calcification upon blockade of FGF23 signalling [22], could possibly be circumvented using inhibitors targeting particular FGFR subtypes.

#### Monoclonal antibodies against FGFs and FGFRs

Monoclonal antibodies targeting RTKs or their ligands can block ligand binding and receptor dimerization, and may act to promote tumour cell removal by the immune system [13,186,189]. This strategy has been successfully used for treatment of various types of cancer with deregulated RTKs [11,13,189]. Importantly, monoclonal antibodies can be produced that very specifically bind their targets due to high specificity in antibody–antigen interactions [189]. This holds promise for the generation of highly specific antibodies that target particular FGF or FGFR isoforms [186]. Since monoclonal antibodies act extracellularly, they may be relevant to use in cancers that overexpress FGFs or FGFRs, or display activating FGFR mutations, but probably not in cancers

with cytoplasmic chimaeric proteins consisting of dimerization domains fused to FGFR kinase domains.

Currently there are several ongoing efforts to generate monoclonal antibodies against FGFs or FGFRs [12,22,186]. Monoclonal antibodies against FGFs have shown anti-tumour activity in mouse models of, for example, breast and prostate cancer (FGF8), as well as colon and hepatocellular cancer (FGF19) and melanoma (FGF2) [99,127,190,191]. Also, monoclonal antibodies against the FGFRs have shown anti-tumour effects in mouse models and cancer cell lines. For example, R3Mab and PRO-001 that inhibit ligand binding to and dimerization of FGFRs, exhibited potent anti-tumour activity in mouse models of MM and bladder cancer overexpressing FGFR3 [108,161]. Furthermore, a monoclonal antibody (GP369) targeting the FGFR2 IIIb isoform has been shown to inhibit growth of human breast and gastric cancer xenografts with activated FGFR2 signalling in mice [192]. These studies indicate that monoclonal antibodies targeting specific FGF or FGFR isoforms can be generated and provide proof-of-principle that therapeutic antibodies against FGFs/FGFRs may have the potential to be used in cancer therapy. It remains to be determined whether monoclonal antibodies targeting FGFs/FGFRs will show promising results in clinical trials.

### FGF ligand traps

Another strategy to interfere with FGFR signalling is represented by so-called FGF ligand traps that sequester FGF ligands to prevent their binding to FGFRs. FGF traps may be most useful in cancers displaying FGF overexpression. The FGF trap FP-1039 (Five Prime Therapeutics) is a soluble fusion protein consisting of the extracellular FGFR1 IIIc domain fused to the Fc portion of IgG1. It prevents FGF1, FGF2 and FGF4 from binding to their respective receptors, thereby inhibiting FGFR kinase activation and therefore potentially blocking FGFR-induced proliferation and angiogenesis. This FGF trap is going to be used in Phase II clinical trials to test its activity and safety in advanced or recurrent endometrial cancers with specific FGFR2 mutations (<http://ClinicalTrials.gov>).

### CONCLUDING REMARKS

In summary, deregulation of FGFs and FGFRs is detected in a number of solid human tumours and haematological malignancies, and may sustain several of the cancer hallmarks. In particular, FGFs and FGFRs seem to act oncogenically to stimulate several steps of cancer progression, including cancer cell proliferation and survival, as well as EMT, invasion/metastasis and angiogenesis. Targeting FGFs/FGFRs in cancer is relatively new and it remains to be seen whether ongoing clinical trials and future developments will appear promising in the treatment of human cancer. Despite promising examples of the use of molecular-targeted therapies against RTKs, a number of challenges still exist, as shown in the case of the FGFR. Moreover, an obstacle experienced with both small-molecule tyrosine kinase inhibitors and monoclonal antibody therapies is the development of resistance in patients owing to the emergence of mutations that give rise to drug-resistant RTK variants or compensatory signalling networks to overcome the need for the inhibited RTK [11,13]. Moreover, since the responses to small-molecule tyrosine kinase inhibitors and monoclonal antibodies are often low or moderate, they usually need to be used in combination with chemo- or radio-therapy to achieve enhanced responses [193]. Future challenges in targeting FGFs/FGFRs in cancer therapy

include increasing the knowledge about the effect of FGFRs in progression of specific cancer types, the development of FGFR therapeutics with few side effects, and the development of diagnostic and prognostic biomarkers to enable appropriate patient selection for cancer treatment.

### ACKNOWLEDGEMENTS

We sincerely apologize for the many studies that could not be cited due to space restrictions.

### FUNDING

E.M.H is a postdoctoral fellow of the Norwegian Cancer Society and J.W. has a research fellowship from the South-Eastern Norway Regional Health Authority. K.H. holds a senior scientist grant from the Research Council of Norway.

### REFERENCES

- Hanahan, D. and Weinberg, R. A. (2000) The hallmarks of cancer. *Cell* **100**, 57–70
- Hanahan, D. and Weinberg, R. A. (2011) Hallmarks of cancer: the next generation. *Cell* **144**, 646–674
- Negrini, S., Gorgoulis, V. G. and Halazonetis, T. D. (2010) Genomic instability: an evolving hallmark of cancer. *Nat. Rev. Mol. Cell Biol.* **11**, 220–228
- Luo, J., Solimini, N. L. and Elledge, S. J. (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. *Cell* **136**, 823–837
- Kroemer, G. and Pouyssegur, J. (2008) Tumor cell metabolism: cancer's Achilles' heel. *Cancer Cell* **13**, 472–482
- Colotta, F., Allavena, P., Sica, A., Garlanda, C. and Mantovani, A. (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. *Carcinogenesis* **30**, 1073–1081
- Hahn, W. C. and Weinberg, R. A. (2002) Rules for making human tumor cells. *N. Engl. J. Med.* **347**, 1593–1603
- Stratton, M. R., Campbell, P. J. and Futreal, P. A. (2009) The cancer genome. *Nature* **458**, 719–724
- Weinstein, I. B. and Joe, A. (2008) Oncogene addiction. *Cancer Res.* **68**, 3077–3080
- Schlessinger, J. (2000) Cell signaling by receptor tyrosine kinases. *Cell* **103**, 211–225
- Lemmon, M. A. and Schlessinger, J. (2010) Cell signaling by receptor tyrosine kinases. *Cell* **141**, 1117–1134
- Beenken, A. and Mohammadi, M. (2009) The FGF family: biology, pathophysiology and therapy. *Nat. Rev. Drug Discovery* **8**, 235–253
- Witsch, E., Sela, M. and Yarden, Y. (2010) Roles for growth factors in cancer progression. *Physiology* **25**, 85–101
- Greenman, C., Stephens, P., Smith, R., Dalgleish, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C. et al. (2007) Patterns of somatic mutation in human cancer genomes. *Nature* **446**, 153–158
- Mosesson, Y., Mills, G. B. and Yarden, Y. (2008) Derailed endocytosis: an emerging feature of cancer. *Nat. Rev. Cancer* **8**, 835–850
- Haglund, K., Rusten, T. E. and Stenmark, H. (2007) Aberrant receptor signaling and trafficking as mechanisms in oncogenesis. *Crit. Rev. Oncog.* **13**, 39–74
- Abella, J. V. and Park, M. (2009) Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. *Am. J. Physiol. Endocrinol. Metab.* **296**, E973–E984
- Yilmaz, M. and Christofori, G. (2009) EMT, the cytoskeleton, and cancer cell invasion. *Cancer Metastasis Rev.* **28**, 15–33
- Seton-Rogers, S. E. and Brugge, J. S. (2004) ErbB2 and TGF- $\beta$ : a cooperative role in mammary tumor progression? *Cell Cycle* **3**, 597–600
- Geiger, T. R. and Peepker, D. S. (2009) Metastasis mechanisms. *Biochim. Biophys. Acta* **1796**, 293–308
- Nussenbaum, F. and Herman, I. M. (2010) Tumor angiogenesis: insights and innovations. *J. Oncol.* **2010**, 132641
- Turner, N. and Grose, R. (2010) Fibroblast growth factor signalling: from development to cancer. *Nat. Rev. Cancer* **10**, 116–129
- Johnson, D. E. and Williams, L. T. (1993) Structural and functional diversity in the FGF receptor multigene family. *Adv. Cancer Res.* **60**, 1–41
- Olsen, S. K., Ibrahim, O. A., Raucchi, A., Zhang, F., Eliseenkova, A. V., Yayon, A., Basilico, C., Linhardt, R. J., Schlessinger, J. and Mohammadi, M. (2004) Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 935–940

- 25 Ornitz, D. M., Xu, J., Colvin, J. S., McEwen, D. G., MacArthur, C. A., Coulier, F., Gao, G. and Goldfarb, M. (1996) Receptor specificity of the fibroblast growth factor family. *J. Biol. Chem.* **271**, 15292–15297
- 26 Mohammadi, M., Dikic, I., Sorokin, A., Burgess, W. H., Jaye, M. and Schlessinger, J. (1996) Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. *Mol. Cell. Biol.* **16**, 977–989
- 27 Mohammadi, M., Honegger, A. M., Rotin, D., Fischer, R., Bellot, F., Li, W., Dionne, C. A., Jaye, M., Rubinstein, M. and Schlessinger, J. (1991) A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Fgf) is a binding site for the SH2 domain of phospholipase C- $\gamma$ 1. *Mol. Cell. Biol.* **11**, 5068–5078
- 28 Eswarakumar, V. P., Lax, I. and Schlessinger, J. (2005) Cellular signaling by fibroblast growth factor receptors. *Cytokine Growth Factor Rev.* **16**, 139–149
- 29 Casci, T., Vinos, J. and Freeman, M. (1999) Sprouty, an intracellular inhibitor of Ras signaling. *Cell* **96**, 655–665
- 30 Cabrera, M. A. and Christofori, G. (2008) Sprouty proteins, masterminds of receptor tyrosine kinase signaling. *Angiogenesis* **11**, 53–62
- 31 Hacohen, N., Kramer, S., Sutherland, D., Hiromi, Y. and Krasnow, M. A. (1998) Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the *Drosophila* airways. *Cell* **92**, 253–263
- 32 Martinez, N., Garcia-Dominguez, C. A., Domingo, B., Oliva, J. L., Zarich, N., Sanchez, A., Gutierrez-Eisman, S., Llopis, J. and Rojas, J. M. (2007) Sprouty2 binds Grb2 at two different proline-rich regions, and the mechanism of ERK inhibition is independent of this interaction. *Cell. Signalling* **19**, 2277–2285
- 33 Li, C., Scott, D. A., Hatch, E., Tian, X. and Mansour, S. L. (2007) Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development. *Development* **134**, 167–176
- 34 Kovalenko, D., Yang, X., Nadeau, R. J., Harkins, L. K. and Friesel, R. (2003) Sef inhibits fibroblast growth factor signaling by inhibiting FGFR1 tyrosine phosphorylation and subsequent ERK activation. *J. Biol. Chem.* **278**, 14087–14091
- 35 Tsang, M. and Dawid, I. B. (2004) Promotion and attenuation of FGF signaling through the Ras-MAPK pathway. *Sci. STKE* **2004**, e17
- 36 Lax, I., Wong, A., Lamothe, B., Lee, A., Frost, A., Hawes, J. and Schlessinger, J. (2002) The docking protein FRS2 $\alpha$  controls a MAP kinase-mediated negative feedback mechanism for signaling by FGF receptors. *Mol. Cell* **10**, 709–719
- 37 Bottcher, R. T., Pollet, N., Delius, H. and Niehrs, C. (2004) The transmembrane protein XFLRT3 forms a complex with FGF receptors and promotes FGF signalling. *Nat. Cell Biol.* **6**, 38–44
- 38 Haines, B. P., Wheldon, L. M., Summerbell, D., Heath, J. K. and Rigby, P. W. (2006) Regulated expression of FLRT genes implies a functional role in the regulation of FGF signalling during mouse development. *Dev. Biol.* **297**, 14–25
- 39 Wong, A., Lamothe, B., Lee, A., Schlessinger, J. and Lax, I. (2002) FRS2 $\alpha$  attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl. *Proc. Natl. Acad. Sci. U.S.A.* **99**, 6684–6689
- 40 Haugsten, E. M., Malecki, J., Bjorklund, S. M., Olsnes, S. and Wesche, J. (2008) Ubiquitination of fibroblast growth factor receptor 1 is required for its intracellular sorting but not for its endocytosis. *Mol. Cell Biol.* **19**, 3390–3403
- 41 Jean, S., Mikryukov, A., Tremblay, M. G., Baril, J., Guillou, F., Bellenfant, S. and Moss, T. (2010) Extended-synaptotagmin-2 mediates FGF receptor endocytosis and ERK activation *in vivo*. *Dev. Cell* **19**, 426–439
- 42 Haugsten, E. M., Sorensen, V., Brech, A., Olsnes, S. and Wesche, J. (2005) Different intracellular trafficking of FGF1 endocytosed by the four homologous FGF receptors. *J. Cell Sci.* **118**, 3869–3881
- 43 Belleudi, F., Leone, L., Maggio, M. and Torrisi, M. R. (2009) Hrs regulates the endocytic sorting of the fibroblast growth factor receptor 2b. *Exp. Cell Res.* **315**, 2181–2191
- 44 Mardakheh, F. K., Yekezare, M., Machesky, L. M. and Heath, J. K. (2009) Spred2 interaction with the late endosomal protein NBR1 down-regulates fibroblast growth factor receptor signaling. *J. Cell Biol.* **187**, 265–277
- 45 Belleudi, F., Leone, L., Nobili, V., Raffa, S., Francescangeli, F., Maggio, M., Morrone, S., Marchese, C. and Torrisi, M. R. (2007) Keratinocyte growth factor receptor ligands target the receptor to different intracellular pathways. *Traffic* **8**, 1854–1872
- 46 Francavilla, C., Cattaneo, P., Berezin, V., Bock, E., Ami, D., de Marco, A., Christofori, G. and Cavallaro, U. (2009) The binding of NCAM to FGFR1 induces a specific cellular response mediated by receptor trafficking. *J. Cell Biol.* **187**, 1101–1116
- 47 Powers, C. J., McLeskey, S. W. and Wellstein, A. (2000) Fibroblast growth factors, their receptors and signaling. *Endocr. Relat. Cancer* **7**, 165–197
- 48 Presta, M., Dell'Era, P., Mitola, S., Moroni, E., Ronca, R. and Rusnati, M. (2005) Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. *Cytokine Growth Factor Rev.* **16**, 159–178
- 49 Lanner, F. and Rossant, J. (2010) The role of FGF/Erk signaling in pluripotent cells. *Development* **137**, 3351–3360
- 50 Taylor, J. G., Cheuk, A. T., Tsang, P. S., Chung, J. Y., Song, Y. K., Desai, K., Yu, Y., Chen, Q. R., Shah, K., Youngblood, V. et al. (2009) Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. *J. Clin. Invest.* **119**, 3395–3407
- 51 Elbaoumy, E. S., Green, A. R., Lambros, M. B., Turner, N. C., Grainge, M. J., Powe, D., Ellis, I. O. and Reis-Filho, J. S. (2007) FGFR1 amplification in breast carcinomas: a chromogenic *in situ* hybridisation analysis. *Breast Cancer Res.* **9**, R23
- 52 Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B. et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. *Nature* **455**, 1069–1075
- 53 Turner, N., Pearson, A., Sharpe, R., Lambros, M., Geyer, F., Lopez-Garcia, M. A., Natrajan, R., Marchio, C., Iorns, E., Mackay, A. et al. (2010) FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. *Cancer Res.* **70**, 2085–2094
- 54 Beroukhi, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M. et al. (2010) The landscape of somatic copy-number alteration across human cancers. *Nature* **463**, 899–905
- 55 Dutt, A., Salvesen, H. B., Chen, T. H., Ramos, A. H., Onofrio, R. C., Hatton, C., Nicoletti, R., Winckler, W., Grewal, R., Hanna, M. et al. (2008) Drug-sensitive FGFR2 mutations in endometrial carcinoma. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 8713–8717
- 56 Weiss, J., Sos, M. L., Seidel, D., Peifer, M., Zander, T., Heuckmann, J. M., Ullrich, R. T., Menon, R., Maier, S., Soltermann, A. et al. (2010) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. *Sci. Transl. Med.* **2**, 62ra93
- 57 Wilkie, A. O. (2005) Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. *Cytokine Growth Factor Rev.* **16**, 187–203
- 58 Naski, M. C., Wang, Q., Xu, J. and Ornitz, D. M. (1996) Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. *Nat. Genet.* **13**, 233–237
- 59 d'Avic, P. Y., Robertson, S. C., Meyer, A. N., Bardwell, W. M., Webster, M. K. and Donoghue, D. J. (1998) Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. *Cell Growth Differ.* **9**, 71–78
- 60 Pandith, A. A., Shah, Z. A. and Siddiqi, M. A. (2010) Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer. *Urol. Oncol.*, doi:10.1016/j.urolonc.2010.07.014
- 61 Pollock, P. M., Gartside, M. G., Dejeza, L. C., Powell, M. A., Mallon, M. A., Davies, H., Mohammadi, M., Futreal, P. A., Stratton, M. R., Trent, J. M. and Goodfellow, P. J. (2007) Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. *Oncogene* **26**, 7158–7162
- 62 Gartside, M. G., Chen, H., Ibrahim, O. A., Byron, S. A., Curtis, A. V., Wellens, C. L., Bengston, A., Yudit, L. M., Eliseenkova, A. V., Ma, J. et al. (2009) Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. *Mol. Cancer Res.* **7**, 41–54
- 63 Abdel-Rahman, W. M., Kalinina, J., Shoman, S., Eissa, S., Ollikainen, M., Elomaa, O., Eliseenkova, A. V., Butzow, R., Mohammadi, M. and Peltomaki, P. (2008) Somatic FGF9 mutations in colorectal and endometrial carcinomas associated with membranous  $\beta$ -catenin. *Hum. Mutat.* **29**, 390–397
- 64 Bange, J., Prechtel, D., Cheburkin, Y., Specht, K., Harbeck, N., Schmitt, M., Knyazeva, T., Muller, S., Gartner, S., Sures, I. et al. (2002) Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. *Cancer Res.* **62**, 840–847
- 65 Sugiyama, N., Varjosalo, M., Meller, P., Lohi, J., Hyytiainen, M., Kilpinen, S., Kallioniemi, O., Ingvarsen, S., Engelholm, L. H., Taipale, J. et al. (2010) Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation. *Cancer Res.* **70**, 7851–7861
- 66 Spinola, M., Leoni, V., Pignatiello, C., Conti, B., Ravagnani, F., Pastorino, U. and Dragani, T. A. (2005) Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. *J. Clin. Oncol.* **23**, 7307–7311
- 67 Spinola, M., Leoni, V. P., Tanuma, J., Pettinicchio, A., Frattini, M., Signoroni, S., Agresti, R., Giovanazzi, R., Pilotti, S., Bertario, L. et al. (2005) FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. *Oncol. Rep.* **14**, 415–419
- 68 Thussbs, C., Nahrig, J., Streit, S., Bange, J., Kriner, M., Kates, R., Ulm, K., Kiechle, M., Hoefler, H., Ullrich, A. and Harbeck, N. (2006) FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. *J. Clin. Oncol.* **24**, 3747–3755
- 69 Wang, J., Yu, W., Cai, Y., Ren, C. and Iltmann, M. M. (2008) Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. *Neoplasia* **10**, 847–856
- 70 Sugiyama, N., Varjosalo, M., Meller, P., Lohi, J., Chan, K. M., Zhou, Z., Alitalo, K., Taipale, J., Keski-Oja, J. and Lehti, K. (2010) FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase-FGFR4 complex. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 15786–15791

- 71 Hunter, D. J., Kraft, P., Jacobs, K. B., Cox, D. G., Yeager, M., Hankinson, S. E., Wacholder, S., Wang, Z., Welch, R., Hutchinson, A. et al. (2007) A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. *Nat. Genet.* **39**, 870–874
- 72 Easton, D. F., Pooley, K. A., Dunning, A. M., Pharoah, P. D., Thompson, D., Ballinger, D. G., Struwing, J. P., Morrison, J., Field, H., Luben, R. et al. (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature* **447**, 1087–1093
- 73 Jackson, C. C., Medeiros, L. J. and Miranda, R. N. (2010) 8p11 myeloproliferative syndrome: a review. *Hum. Pathol.* **41**, 461–476
- 74 Gelsi-Boyer, V., Orsetti, B., Cervera, N., Finetti, P., Sircoulomb, F., Rouge, C., Lasorsa, L., Letessier, A., Ginestier, C., Monville, F. et al. (2005) Comprehensive profiling of 8p11-12 amplification in breast cancer. *Mol. Cancer Res.* **3**, 655–667
- 75 Chin, K., DeVries, S., Fridlyand, J., Spellman, P. T., Roydasgupta, R., Kuo, W. L., Lapuk, A., Neve, R. M., Qian, Z., Ryder, T. et al. (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. *Cancer Cell* **10**, 529–541
- 76 Letessier, A., Sircoulomb, F., Ginestier, C., Cervera, N., Monville, F., Gelsi-Boyer, V., Esterni, B., Geneix, J., Finetti, P., Zemmour, C. et al. (2006) Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. *BMC Cancer* **6**, 245
- 77 Cho, J. Y., Guo, C., Torello, M., Lunstrum, G. P., Iwata, T., Deng, C. and Horton, W. A. (2004) Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 609–614
- 78 Cha, J. Y., Maddileti, S., Mitin, N., Harden, T. K. and Der, C. J. (2009) Aberrant receptor internalization and enhanced FRS2-dependent signaling contribute to the transforming activity of the fibroblast growth factor receptor 2 IIIb C3 isoform. *J. Biol. Chem.* **284**, 6227–6240
- 79 Fritzsche, S., Kenzelmann, M., Hoffmann, M. J., Muller, M., Engers, R., Grone, H. J. and Schulz, W. A. (2006) Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma. *Endocr. Relat. Cancer* **13**, 839–849
- 80 Darby, S., Murphy, T., Thomas, H., Robson, C. N., Leung, H. Y., Mathers, M. E. and Gnanapragasam, V. J. (2009) Similar expression to FGF (Sef) inhibits fibroblast growth factor-induced tumorigenic behaviour in prostate cancer cells and is downregulated in aggressive clinical disease. *Br. J. Cancer* **101**, 1891–1899
- 81 Mailleux, A. A., Spencer-Dene, B., Dillon, C., Ndiaye, D., Savona-Baron, C., Itoh, N., Kato, S., Dickson, C., Thiery, J. P. and Bellusci, S. (2002) Role of FGF10/FGFR2b signaling during mammary gland development in the mouse embryo. *Development* **129**, 53–60
- 82 Xu, W., Li, Y., Wang, X., Chen, B., Wang, Y., Liu, S., Xu, J., Zhao, W. and Wu, J. (2010) FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis including 8555 subjects. *Eur. J. Cancer* **46**, 3332–3338
- 83 Parsa, S., Ramasamy, S. K., De, L. S., Gupte, V. V., Haigh, J. J., Medina, D. and Bellusci, S. (2008) Terminal end bud maintenance in mammary gland is dependent upon FGFR2b signaling. *Dev. Biol.* **317**, 121–131
- 84 Xian, W., Pappas, L., Pandya, D., Selfors, L. M., Derksen, P. W., de Bruin, M., Gray, N. S., Jonkers, J., Rosen, J. M. and Brugge, J. S. (2009) Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. *Cancer Res.* **69**, 2244–2251
- 85 Xian, W., Schwertfeger, K. L., Vargo-Gogola, T. and Rosen, J. M. (2005) Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model. *J. Cell Biol.* **171**, 663–673
- 86 Welm, B. E., Freeman, K. W., Chen, M., Contreras, A., Spencer, D. M. and Rosen, J. M. (2002) Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland. *J. Cell Biol.* **157**, 703–714
- 87 Ray, M. E., Yang, Z. Q., Albertson, D., Kleer, C. G., Washburn, J. G., Macoska, J. A. and Ethier, S. P. (2004) Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines. *Cancer Res.* **64**, 40–47
- 88 Bernard-Pierrot, I., Gruel, N., Stransky, N., Vincent-Salomon, A., Reyat, F., Raynal, V., Vallot, C., Pierron, G., Radvanyi, F. and Delattre, O. (2008) Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer. *Cancer Res.* **68**, 7165–7175
- 89 Garcia, M. J., Pole, J. C., Chin, S. F., Teschendorff, A., Naderi, A., Ozdag, H., Vias, M., Kranjac, T., Subkhankulova, T., Paish, C. et al. (2005) A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. *Oncogene* **24**, 5235–5245
- 90 Turner, N., Lambros, M. B., Horlings, H. M., Pearson, A., Sharpe, R., Natrajan, R., Geyer, F. C., van Kouwenhove, M., Kreike, B., Mackay, A. et al. (2010) Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. *Oncogene* **29**, 2013–2023
- 91 Schneider, B. P., Winer, E. P., Foulkes, W. D., Garber, J., Perou, C. M., Richardson, A., Sledge, G. W. and Carey, L. A. (2008) Triple-negative breast cancer: risk factors to potential targets. *Clin. Cancer Res.* **14**, 8010–8018
- 92 Penault-Llorca, F., Bertucci, F., Adelaide, J., Parc, P., Coulier, F., Jacquemier, J., Birnbaum, D. and deLapeyriere, O. (1995) Expression of FGF and FGF receptor genes in human breast cancer. *Int. J. Cancer* **61**, 170–176
- 93 Roidl, A., Berger, H. J., Kumar, S., Bange, J., Knyazev, P. and Ullrich, A. (2009) Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. *Clin. Cancer Res.* **15**, 2058–2066
- 94 Fioravanti, L., Cappelletti, V., Coradini, D., Miodini, P., Borsani, G., Daidone, M. G. and Di Fronzo, G. (1997) Int-2 oncogene amplification and prognosis in node-negative breast carcinoma. *Int. J. Cancer* **74**, 620–624
- 95 Gruel, N., Lucchesi, C., Raynal, V., Rodrigues, M. J., Pierron, G., Goudefroye, R., Cottu, P., Reyat, F., Sastre-Garau, X., Fourquet, A. et al. (2010) Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma. *Eur. J. Cancer* **46**, 2399–2407
- 96 Naidu, R., Wahab, N. A., Yadav, M., Kutty, M. K. and Nair, S. (2001) Detection of amplified int-2/FGF-3 gene in primary breast carcinomas using differential polymerase chain reaction. *Int. J. Mol. Med.* **8**, 193–198
- 97 Marsh, S. K., Bansal, G. S., Zammit, C., Barnard, R., Coope, R., Roberts-Clarke, D., Gomm, J. J., Coombes, R. C. and Johnston, C. L. (1999) Increased expression of fibroblast growth factor 8 in human breast cancer. *Oncogene* **18**, 1053–1060
- 98 Mattila, M. M. and Harkonen, P. L. (2007) Role of fibroblast growth factor 8 in growth and progression of hormonal cancer. *Cytokine Growth Factor Rev.* **18**, 257–266
- 99 Shimada, N., Ishii, T., Imada, T., Takaba, K., Sasaki, Y., Maruyama-Takahashi, K., Maekawa-Tokuda, Y., Kusaka, H., Akinaga, S., Tanaka, A. and Shitara, K. (2005) A neutralizing anti-fibroblast growth factor 8 monoclonal antibody shows potent antitumor activity against androgen-dependent mouse mammary tumors *in vivo*. *Clin. Cancer Res.* **11**, 3897–3904
- 100 Theodorou, V., Boer, M., Weigelt, B., Jonkers, J., van der Valk, V. and Hilken, J. (2004) Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas. *Oncogene* **23**, 6047–6055
- 101 Jacobs, B. L., Lee, C. T. and Montie, J. E. (2010) Bladder cancer in 2010: how far have we come? *CA Cancer J. Clin.* **60**, 244–272
- 102 Wu, X. R. (2005) Urothelial tumorigenesis: a tale of divergent pathways. *Nat. Rev. Cancer* **5**, 713–725
- 103 Cappelletti, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J. P. and Radvanyi, F. (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. *Nat. Genet.* **23**, 18–20
- 104 Hernandez, S., Lopez-Knowles, E., Lloreta, J., Kogevinas, M., Amoros, A., Tardon, A., Carrato, A., Serra, C., Malats, N. and Real, F. X. (2006) Prospective study of FGFR3 mutations as a prognostic factor in non-muscle invasive urothelial bladder carcinomas. *J. Clin. Oncol.* **24**, 3664–3671
- 105 van Rhijn, B. W., van Tilborg, A. A., Lurkin, I., Bonaventure, J., de Vries, A., Thiery, J. P., van der Kwast, T. H., Zwarthoff, E. C. and Radvanyi, F. (2002) Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. *Eur. J. Hum. Genet.* **10**, 819–824
- 106 Tomlinson, D. C., Baldo, O., Harnden, P. and Knowles, M. A. (2007) FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. *J. Pathol.* **213**, 91–98
- 107 Bernard-Pierrot, I., Brams, A., Dunois-Larde, C., Caillaud, A., Diez de Medina, S. G., Cappelletti, D., Graff, G., Thiery, J. P., Chopin, D., Ricol, D. and Radvanyi, F. (2006) Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. *Carcinogenesis* **27**, 740–747
- 108 Qing, J., Du, X., Chen, Y., Chan, P., Li, H., Wu, P., Marsters, S., Stawicki, S., Tien, J., Totpal, K. et al. (2009) Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. *J. Clin. Invest.* **119**, 1216–1229
- 109 Miyake, M., Ishii, M., Koyama, N., Kawashima, K., Kodama, T., Anai, S., Fujimoto, K., Hirao, Y. and Sugano, K. (2010) PD173074, a selective tyrosine kinase inhibitor of FGFR3, inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest. *J. Pharmacol. Exp. Ther.* **332**, 795–802
- 110 Tomlinson, D. C., Hurst, C. D. and Knowles, M. A. (2007) Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. *Oncogene* **26**, 5889–5899
- 111 Lamont, F. R., Tomlinson, D. C., Cooper, P. A., Shnyder, S. D., Chester, J. D. and Knowles, M. A. (2011) Small molecule FGF receptor inhibitors block FGF-dependent urothelial carcinoma growth *in vitro* and *in vivo*. *Br. J. Cancer* **104**, 75–82
- 112 Sangar, V. K., Ragavan, N., Matanhelia, S. S., Watson, M. W. and Blades, R. A. (2005) The economic consequences of prostate and bladder cancer in the UK. *BJU Int.* **95**, 59–63

- 113 Miyake, M., Sugano, K., Sugino, H., Imai, K., Matsumoto, E., Maeda, K., Fukuzono, S., Ichikawa, H., Kawashima, K., Hirabayashi, K. et al. (2010) Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer. *Cancer Sci.* **101**, 250–258
- 114 Zuiverloon, T. C., van der Aa, M. N., van der Kwast, T. H., Steyerberg, E. W., Lingsma, H. F., Bangma, C. H. and Zwarthoff, E. C. (2010) Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. *Clin. Cancer Res.* **16**, 3011–3018
- 115 Marzioni, D., Lorenzi, T., Mazzucchelli, R., Capparuccia, L., Morroni, M., Fiorini, R., Bracalenti, C., Catalano, A., David, G., Castellucci, M. et al. (2009) Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer. *Int. J. Immunopathol. Pharmacol.* **22**, 627–638
- 116 Tomlinson, D. C., Lamont, F. R., Shnyder, S. D. and Knowles, M. A. (2009) Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. *Cancer Res.* **69**, 4613–4620
- 117 Diez de Medina, S. G., Chopin, D., El Marjou, A., Delouvee, A., LaRochelle, W. J., Hoznek, A., Abbou, C., Aaronson, S. A., Thiery, J. P. and Radvanyi, F. (1997) Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas. *Oncogene* **14**, 323–330
- 118 Karliou, M., Tzelepi, V. and Efstathiou, E. (2010) Therapeutic targeting of the prostate cancer microenvironment. *Nat. Rev. Urol.* **7**, 494–509
- 119 Kwabi-Addo, B., Ozen, M. and Iltmann, M. (2004) The role of fibroblast growth factors and their receptors in prostate cancer. *Endocr. Relat. Cancer* **11**, 709–724
- 120 Murphy, T., Darby, S., Mathers, M. E. and Gnanapragasam, V. J. (2010) Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype. *J. Pathol.* **220**, 452–460
- 121 Yang, F., Strand, D. W. and Rowley, D. R. (2008) Fibroblast growth factor-2 mediates transforming growth factor- $\beta$  action in prostate cancer reactive stroma. *Oncogene* **27**, 450–459
- 122 Memarzadeh, S., Xin, L., Mulholland, D. J., Mansukhani, A., Wu, H., Teitell, M. A. and Witte, O. N. (2007) Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. *Cancer Cell* **12**, 572–585
- 123 Dorkin, T. J., Robinson, M. C., Marsh, C., Bjartell, A., Neal, D. E. and Leung, H. Y. (1999) FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. *Oncogene* **18**, 2755–2761
- 124 Song, Z., Wu, X., Powell, W. C., Cardiff, R. D., Cohen, M. B., Tin, R. T., Matusik, R. J., Miller, G. J. and Roy-Burman, P. (2002) Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia. *Cancer Res.* **62**, 5096–5105
- 125 Elo, T. D., Valve, E. M., Seppanen, J. A., Vuorikoski, H. J., Makela, S. I., Poutanen, M., Kujala, P. M. and Harkonen, P. L. (2010) Stromal activation associated with development of prostate cancer in prostate-targeted fibroblast growth factor 8b transgenic mice. *Neoplasia* **12**, 915–927
- 126 Valta, M. P., Tuomela, J., Bjartell, A., Valve, E., Vaananen, H. K. and Harkonen, P. (2008) FGF-8 is involved in bone metastasis of prostate cancer. *Int. J. Cancer* **123**, 22–31
- 127 Maruyama-Takahashi, K., Shimada, N., Imada, T., Maekawa-Tokuda, Y., Ishii, T., Ouchi, J., Kusaka, H., Miyaji, H., Akinaga, S., Tanaka, A. and Shitara, K. (2008) A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions. *Prostate* **68**, 640–650
- 128 Li, Z. G., Mathew, P., Yang, J., Starbuck, M. W., Zurita, A. J., Liu, J., Sikes, C., Multani, A. S., Efstathiou, E., Lopez, A. et al. (2008) Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. *J. Clin. Invest.* **118**, 2697–2710
- 129 Sahadevan, K., Darby, S., Leung, H. Y., Mathers, M. E., Robson, C. N. and Gnanapragasam, V. J. (2007) Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. *J. Pathol.* **213**, 82–90
- 130 Giri, D., Ropiquet, F. and Iltmann, M. (1999) Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. *Clin. Cancer Res.* **5**, 1063–1071
- 131 Acevedo, V. D., Gangula, R. D., Freeman, K. W., Li, R., Zhang, Y., Wang, F., Ayala, G. E., Peterson, L. E., Iltmann, M. and Spencer, D. M. (2007) Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. *Cancer Cell* **12**, 559–571
- 132 Liu, T., Willmore-Payne, C., Wallander, M. L. and Layfield, L. J. (2011) Utilization of unlabeled probes for the detection of fibroblast growth factor receptor 2 exons 7 and 12 mutations in endometrial carcinoma. *Appl. Immunohistochem. Mol. Morphol.*, doi:10.1097/PAI.0b013e318201dae8
- 133 Byron, S. A., Gartside, M. G., Wellens, C. L., Mallon, M. A., Keenan, J. B., Powell, M. A., Goodfellow, P. J. and Pollock, P. M. (2008) Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. *Cancer Res.* **68**, 6902–6907
- 134 Kumar, V. H. and Ryan, R. M. (2004) Growth factors in the fetal and neonatal lung. *Front. Biosci.* **9**, 464–480
- 135 Warburton, D., El-Hashash, A., Carraro, G., Tiozzo, C., Sala, F., Rogers, O., De Langhe, S., Kemp, P. J., Riccardi, D., Torday, J. et al. (2010) Lung organogenesis. *Curr. Top. Dev. Biol.* **90**, 73–158
- 136 Marek, L., Ware, K. E., Fritzsche, A., Hercule, P., Helton, W. R., Smith, J. E., McDermott, L. A., Coldren, C. D., Nemenoff, R. A., Merrick, D. T. et al. (2009) Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. *Mol. Pharmacol.* **75**, 196–207
- 137 Turner, N. C. and Seckl, M. J. (2010) A therapeutic target for smoking-associated lung cancer. *Sci. Transl. Med.* **2**, 62ps56
- 138 Voortman, J., Lee, J. H., Killian, J. K., Suuriniemi, M., Wang, Y., Lucchi, M., Smith, Jr, W. I., Meltzer, P., Wang, Y. and Giaccone, G. (2010) Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 13040–13045
- 139 Ruotsalainen, T., Joensuu, H., Mattson, K. and Salven, P. (2002) High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer. *Cancer Epidemiol. Biomarkers Prev.* **11**, 1492–1495
- 140 Pardo, O. E., Arcaro, A., Salerno, G., Tetley, T. D., Valovka, T., Gout, I. and Seckl, M. J. (2001) Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells. *Oncogene* **20**, 7658–7667
- 141 Pardo, O. E., Wellbrock, C., Khanzada, U. K., Aubert, M., Arozarena, I., Davidson, S., Bowen, F., Parker, P. J., Filonenko, V. V., Gout, I. T. et al. (2006) FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKC $\epsilon$ , B-Raf and S6K2. *EMBO J.* **25**, 3078–3088
- 142 Pardo, O. E., Latigo, J., Jeffery, R. E., Nye, E., Poulsom, R., Spencer-Dene, B., Lemoine, N. R., Stamp, G. W., Aboagye, E. O. and Seckl, M. J. (2009) The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth *in vitro* and *in vivo*. *Cancer Res.* **69**, 8645–8651
- 143 Pardo, O. E., Arcaro, A., Salerno, G., Raguz, S., Downward, J. and Seckl, M. J. (2002) Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis. *J. Biol. Chem.* **277**, 12040–12046
- 144 Pardo, O. E., Lesay, A., Arcaro, A., Lopes, R., Ng, B. L., Warne, P. H., McNeish, I. A., Tetley, T. D., Lemoine, N. R., Mehmet, H. et al. (2003) Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cells. *Mol. Cell. Biol.* **23**, 7600–7610
- 145 Davies, H., Hunter, C., Smith, R., Stephens, P., Greenman, C., Bignell, G., Teague, J., Butler, A., Edkins, S., Stevens, C. et al. (2005) Somatic mutations of the protein kinase gene family in human lung cancer. *Cancer Res.* **65**, 7591–7595
- 146 Lajeunie, E., Heuertz, S., El Ghouzi, V., Martinovic, J., Renier, D., Le Merrer, M. and Bonaventure, J. (2006) Mutation screening in patients with syndromic craniosynostoses indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome. *Eur. J. Hum. Genet.* **14**, 289–298
- 147 Robertson, S. C., Meyer, A. N., Hart, K. C., Galvin, B. D., Webster, M. K. and Donoghue, D. J. (1998) Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain. *Proc. Natl. Acad. Sci. U.S.A.* **95**, 4567–4572
- 148 De Giovanni, C., Landuzzi, L., Nicoletti, G., Lollini, P. L. and Nanni, P. (2009) Molecular and cellular biology of rhabdomyosarcoma. *Future Oncol.* **5**, 1449–1475
- 149 Khan, J., Wei, J. S., Ringner, M., Saal, L. H., Ladanyi, M., Westermann, F., Berthold, F., Schwab, M., Antonescu, C. R., Peterson, C. and Meltzer, P. S. (2001) Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. *Nat. Med.* **7**, 673–679
- 150 Baird, K., Davis, S., Antonescu, C. R., Harper, U. L., Walker, R. L., Chen, Y., Glatfelter, A. A., Duray, P. H. and Meltzer, P. S. (2005) Gene expression profiling of human sarcomas: insights into sarcoma biology. *Cancer Res.* **65**, 9226–9235
- 151 Cao, L., Yu, Y., Bilke, S., Walker, R. L., Mayeenuddin, L. H., Azorsa, D. O., Yang, F., Pineda, M., Helman, L. J. and Meltzer, P. S. (2010) Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. *Cancer Res.* **70**, 6497–6508
- 152 Missiaglia, E., Selve, J., Hamdi, M., Williamson, D., Schaaf, G., Fang, C., Koster, J., Summersgill, B., Messahel, B., Versteeg, R. et al. (2009) Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development. *Genes Chromosomes Cancer* **48**, 455–467
- 153 Wachtel, M., Dettling, M., Koscielniak, E., Stegmaier, S., Treuner, J., Simon-Klingenstein, K., Buhlmann, P., Niggli, F. K. and Schafer, B. W. (2004) Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. *Cancer Res.* **64**, 5539–5545

- 154 Goldstein, M., Meller, I. and Orr-Urtreger, A. (2007) FGFR1 over-expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5' CpG island and abnormal expression of the AKT1, NOG, and BMP4 genes. *Genes Chromosomes Cancer* **46**, 1028–1038
- 155 Hirotsu, M., Setoguchi, T., Matsunoshita, Y., Sasaki, H., Nagao, H., Gao, H., Sugimura, K. and Komiya, S. (2009) Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells. *Br. J. Cancer* **101**, 2030–2037
- 156 Chesi, M., Nardini, E., Brents, L. A., Schrock, E., Ried, T., Kuehl, W. M. and Bergsagel, P. L. (1997) Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. *Nat. Genet.* **16**, 260–264
- 157 Chang, H., Stewart, A. K., Qi, X. Y., Li, Z. H., Yi, Q. L. and Trudel, S. (2005) Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. *Blood* **106**, 353–355
- 158 Keats, J. J., Reiman, T., Belch, A. R. and Pilarski, L. M. (2006) Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma. *Leuk. Lymphoma* **47**, 2289–2300
- 159 Keats, J. J., Reiman, T., Maxwell, C. A., Taylor, B. J., Larratt, L. M., Mant, M. J., Belch, A. R. and Pilarski, L. M. (2003) In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. *Blood* **101**, 1520–1529
- 160 Plowright, E. E., Li, Z., Bergsagel, P. L., Chesi, M., Barber, D. L., Branch, D. R., Hawley, R. G. and Stewart, A. K. (2000) Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. *Blood* **95**, 992–998
- 161 Trudel, S., Stewart, A. K., Rom, E., Wei, E., Li, Z. H., Kotzer, S., Chumakov, I., Singer, Y., Chang, H., Liang, S. B. and Yayon, A. (2006) The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. *Blood* **107**, 4039–4046
- 162 Intini, D., Baldini, L., Fabris, S., Lombardi, L., Ciceri, G., Maiolo, A. T. and Neri, A. (2001) Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). *Br. J. Haematol.* **114**, 362–364
- 163 Ronchetti, D., Greco, A., Compasso, S., Colombo, G., Dell'Era, P., Otsuki, T., Lombardi, L. and Neri, A. (2001) Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. *Oncogene* **20**, 3553–3562
- 164 Chesi, M., Brents, L. A., Ely, S. A., Bais, C., Robbani, D. F., Mesri, E. A., Kuehl, W. M. and Bergsagel, P. L. (2001) Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. *Blood* **97**, 729–736
- 165 Gorbenco, O., Ovcharenko, G., Klymenko, T., Zhyvolou, O., Gaman, N., Volkova, D., Gout, I. and Filonenko, V. (2009) Generation of monoclonal antibody targeting fibroblast growth factor receptor 3. *Hybridoma (Larchmt.)* **28**, 295–300
- 166 Krejci, P., Murakami, S., Prochazkova, J., Trantirek, L., Chlebova, K., Ouyang, Z., Aklia, A., Smutny, J., Bryja, V., Kozubik, A. and Wilcox, W. R. (2010) NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells. *J. Biol. Chem.* **285**, 20644–20653
- 167 Xiao, S., Nalabolu, S. R., Aster, J. C., Ma, J., Abruzzo, L., Jaffe, E. S., Stone, R., Weissman, S. M., Hudson, T. J. and Fletcher, J. A. (1998) FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. *Nat. Genet.* **18**, 84–87
- 168 Wasag, B., Lierman, E., Meeus, P., Cools, J. and Vandenberghe, P. (2011) The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11). *Haematologica*, doi:10.3324/haematol.2010.036558
- 169 Roumiantsev, S., Krause, D. S., Neumann, C. A., Dimitri, C. A., Asiedu, F., Cross, N. C. and Van Etten, R. A. (2004) Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. *Cancer Cell* **5**, 287–298
- 170 Guasch, G., Delaval, B., Arnoulet, C., Xie, M. J., Xerri, L., Sainty, D., Birnbaum, D. and Pebusque, M. J. (2004) FOP-FGFR1 tyrosine kinase, the product of a t(6;8) translocation, induces a fatal myeloproliferative disease in mice. *Blood* **103**, 309–312
- 171 Chen, J., Deangelo, D. J., Kutok, J. L., Williams, I. R., Lee, B. H., Wadleigh, M., Duclos, N., Cohen, S., Adelsperger, J., Okabe, R. et al. (2004) PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 14479–14484
- 172 Ren, M., Li, X. and Cowell, J. K. (2009) Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase. *Blood* **114**, 1576–1584
- 173 Demiroglu, A., Steer, E. J., Heath, C., Taylor, K., Bentley, M., Allen, S. L., Koduru, P., Brody, J. P., Hawson, G., Rodwell, R. et al. (2001) The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. *Blood* **98**, 3778–3783
- 174 Gu, T. L., Goss, V. L., Reeves, C., Popova, L., Nardone, J., Macneill, J., Walters, D. K., Wang, Y., Rush, J., Comb, M. J. et al. (2006) Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. *Blood* **108**, 4202–4204
- 175 Chase, A., Grand, F. H. and Cross, N. C. (2007) Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. *Blood* **110**, 3729–3734
- 176 Zhen, Y., Sorensen, V., Jin, Y., Suo, Z. and Wiedlocha, A. (2007) Indirubin-3'-monoxime inhibits autophosphorylation of FGFR1 and stimulates ERK1/2 activity via p38 MAPK. *Oncogene* **26**, 6372–6385
- 177 Kasyapa, C., Gu, T. L., Nagarajan, L., Polakiewicz, R. and Cowell, J. K. (2009) Phosphorylation of the SSBP2 and ABL proteins by the ZNF198-FGFR1 fusion kinase seen in atypical myeloproliferative disorders as revealed by phosphopeptide-specific MS. *Proteomics* **9**, 3979–3988
- 178 Toyokawa, T., Yashiro, M. and Hirakawa, K. (2009) Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma. *Oncol. Rep.* **21**, 875–880
- 179 Steele, I. A., Edmondson, R. J., Bulmer, J. N., Bolger, B. S., Leung, H. Y. and Davies, B. R. (2001) Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. *Oncogene* **20**, 5878–5887
- 180 Allerstorfer, S., Sonvilla, G., Fischer, H., Spiegel-Kreinecker, S., Gaughofer, C., Setinek, U., Czeck, T., Marosi, C., Buchroithner, J., Pichler, J. et al. (2008) FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities. *Oncogene* **27**, 4180–4190
- 181 Freier, K., Schwaenen, C., Sticht, C., Flechtenmacher, C., Muhling, J., Hofele, C., Radlwimmer, B., Lichter, P. and Joos, S. (2007) Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). *Oral Oncol.* **43**, 60–66
- 182 Rand, V., Huang, J., Stockwell, T., Ferriera, S., Buzko, O., Levy, S., Busam, D., Li, K., Edwards, J. B., Eberhart, C. et al. (2005) Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 14344–14349
- 183 Chou, A., Dekker, N. and Jordan, R. C. (2009) Identification of novel fibroblast growth factor receptor 3 gene mutations in actinic cheilitis and squamous cell carcinoma of the lip. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.* **107**, 535–541
- 184 Jang, J. H., Shin, K. H. and Park, J. G. (2001) Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. *Cancer Res.* **61**, 3541–3543
- 185 Shawver, L. K., Slamon, D. and Ullrich, A. (2002) Smart drugs: tyrosine kinase inhibitors in cancer therapy. *Cancer Cell* **1**, 117–123
- 186 Knights, V. and Cook, S. J. (2010) De-regulated FGF receptors as therapeutic targets in cancer. *Pharmacol. Ther.* **125**, 105–117
- 187 Mohammadi, M., Froum, S., Hamby, J. M., Schroeder, M. C., Panek, R. L., Lu, G. H., Eliseenkova, A. V., Green, D., Schlessinger, J. and Hubbard, S. R. (1998) Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. *EMBO J.* **17**, 5896–5904
- 188 de Brito, L. R., Batey, M. A., Zhao, Y., Squires, M. S., Maitland, H., Leung, H. Y., Hall, A. G., Jackson, G., Newell, D. R. and Irving, J. A. (2011) Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma. *Leuk. Res.*, doi:10.1016/j.leukres.2011.01.011
- 189 Reichert, J. M. and Valge-Archer, V. E. (2007) Development trends for monoclonal antibody cancer therapeutics. *Nat. Rev. Drug Discovery* **6**, 349–356
- 190 Desnoyers, L. R., Pai, R., Ferrando, R. E., Hotzel, K., Le, T., Ross, J., Carano, R., D'Souza, A., Qing, J., Mohtashemi, I. et al. (2008) Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. *Oncogene* **27**, 85–97
- 191 Li, D., Wang, H., Xiang, J. J., Deng, N., Wang, P. P., Kang, Y. L., Tao, J. and Xu, M. (2010) Monoclonal antibodies targeting basic fibroblast growth factor inhibit the growth of B16 melanoma *in vivo* and *in vitro*. *Oncol. Rep.* **24**, 457–463
- 192 Bai, A., Meetze, K., Vo, N. Y., Kollipara, S., Mazza, E. K., Winston, W. M., Weiler, S., Poling, L. L., Chen, T., Ismail, N. S. et al. (2010) GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. *Cancer Res.* **70**, 7630–7639
- 193 Baselga, J. (2006) Targeting tyrosine kinases in cancer: the second wave. *Science* **312**, 1175–1178

## SUPPLEMENTARY ONLINE DATA

# Fibroblast growth factors and their receptors in cancer

Jørgen WESCHE<sup>1</sup>, Kaisa HAGLUND and Ellen Margrethe HAUGSTEN

Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway and Department of Biochemistry, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Montebello, 0310 Oslo, Norway

Supplementary Tables S1–S3 are on the following pages.

<sup>1</sup> To whom correspondence should be addressed (email [Jorgen.Wesche@rr-research.no](mailto:Jorgen.Wesche@rr-research.no)).



**Table S1 Altered expression of FGFRs reported in human cancers**

MPD, myeloproliferative disorders

Cancer type	Receptor	Up-regulated (references)	Down-regulated (references)	Other
Brain	FGFR1	[1–5]		
	FGFR2	[6]	[7,8]	
	FGFR4	[9]		
Head and neck	FGFR1	[10–17]		
	FGFR2	[16–21]	[22]	
	FGFR4	[19,20,23,24]		
Sarcoma	FGFR1	[25]		
		[26,27]		Chondrosarcoma
		[28]		Osteosarcoma
Soft tissue sarcoma	FGFR2	[28]		Osteosarcoma
	FGFR3	[28]		Osteosarcoma
	FGFR1	[29,30]		Rhabdomyosarcoma
Thyroid		[31]		Cystosarcoma
	FGFR2	[32]		Kaposi's sarcoma
		[33]		Rhabdomyosarcoma
	FGFR3	[34]		Rhabdomyosarcoma
	FGFR4	[28,33,35–39]		Rhabdomyosarcoma
	FGFR1	[40,41]		
Lung	FGFR2		[42]	
	FGFR3	[40]		
	FGFR4	[40]		
	FGFR1	[43–53]		
Breast	FGFR2	[45–48,54–56]		
	FGFR3	[45,46,57,58]		
	FGFR4	[45]	[59]	
	FGFR1	[60–76]		
Liver	FGFR2	[60,64,73,74,76–79]		
	FGFR3	[80]		
	FGFR4	[74,81,82]		
	FGFR1	[83]		
Pancreas	FGFR2	[84]	[85]	
	FGFR3	[84,86]		
	FGFR4	[84,87,88]		
	FGFR1	[89–93]		
Stomach	FGFR2	[94–96]		
	FGFR3	[92]		
	FGFR4	[92,97]		
	FGFR1	[98,99]		
Bladder	FGFR2	[98,100–110]		
	FGFR4	[98]		
	FGFR1	[111–115]		
Prostate	FGFR2	[111,112]	[116]	
	FGFR3	[117–121]		
	FGFR1	[122–130]		
Testis	FGFR2	[127–129]	[131]	
	FGFR4	[122,123,132,133]		
Colon	FGFR1	[134]		
	FGFR1	[135]	[136]	
Uterus	FGFR3		[137]	
	FGFR1	[138,139]		
Ovary	FGFR2	[140–142]		
	FGFR1	[67,143,144]		
	FGFR2	[145]		
Cervix	FGFR4	[82]		
	FGFR2	[146–148]		
Skin	FGFR1	[149,150]		
	FGFR3	[151,152]		
	FGFR4	[153]		
	FGFR3	[154–171]		
Multiple myeloma Leukaemia/MPD/lymphoma	FGFR1	[172–177]		
	FGFR3	[178–181]		

**Table S2 FGFR point mutations identified in human cancers**

Mutated FGFRs for which functional experiments demonstrated loss-of-function mutations are underlined and gain-of-function mutations are indicated in bold. Normal lettering indicates mutations for which the function has not been determined experimentally. MM, multiple myeloma, RMS, rhabdomyosarcoma, X, stop codon, PS, Pfeiffer syndrome, AS, Apert syndrome, CS, Crouzon syndrome, BSS, Beare–Stevenson syndrome, LADD, Lacrimo-Auriculo-Dento-Digital syndrome, CR, nonsyndromic craniosynostosis, TD, Thanatophoric dysplasia, ACH, Achondroplasia, HCH, Hypochondroplasia, SADDAN, Severe Achondroplasia with Developmental Delay and Acanthosis Nigricans, AN, Acanthosis Nigricans. Note that in the literature some of the mutations are numbered relative to the alternative Igllc or IIIb isoform whereas we here only number the mutations relative to the FGFR1 IIIc (GenBank® accession number NM\_023110), FGFR2 IIIc (GenBank® accession number NP\_000132), FGFR3 IIIc (GenBank® accession number NP\_000133) and FGFR4 (GenBank® accession number X57205).

Receptor	Mutation	Cancer type	Consequence	Syndrome	
FGFR1	G70R [44,182] (SNP)	Lung			
	R78H [183]	Prostate			
	S125L [184,185] S125L [186]	Breast, skin			
	T141R [182] (SNP)	Lung			
	P252T [184,187]	Lung	P252R is associated with PS and results in altered ligand specificity [188]		
	P252S [183]	Skin			
	A268S [183]	Stomach, Colon			
	A429S [189]	Colon			
	<b>N546K</b> [190]	Brain	Enhanced kinase activity [191]		
	R576W [190]	Brain	Predicted to result in enhanced activity [190]		
	P576H	Lung			
	<b>K656E</b> [6]	Brain	Enhanced kinase activity [192]		
	V664L [184]	Lung			
	FGFR2	S24F [193]	Skin		
		M71T [183]	Bladder, lymphoma		
		V77M [193]	Skin		
		A97T [194]	Cervix		
		D101Y [194]	Endometrial		
		E160A [193]	Skin	Predicted to negatively affect interaction with HSPG [193]	
R203C [184,185,195]		Breast			
N211I [194]		Lung			
Q212K [6]		Brain			
H213Y [193]		Skin	Predicted to negatively affect interaction with HSPG [193]		
E219K [193]		Skin	Predicted to reduce receptor dimerization [193]		
G227E [193]		Skin	Predicted to destabilize the Igll domain [193]		
V248D [193]		Skin	Predicted to destabilize the Igll domain [193]		
R251Q [193]		Skin	Loss of ligand binding [193]		
<b>S252W</b> [194,196–198]		Endometrial	Alter ligand specificity [200]	AS [201]	
<b>S252W</b> [199]		Ovary			
<b>P253R</b> [194]		Endometrial	Alter ligand specificity [200]	AS [201]	
<b>S267P</b> [202]		Stomach	Ligand-independent dimerization [203]	CS [201]	
G271E [193]		Skin	Predicted to destabilize the Iglll domain [193]		
G272V [184]		Ovary			
D283N [184,187]		Lung			
W290C [184,187,194]		Lung	W290G forms ligand-independent dimers [204]	PS [205]	
G305R [193]		Skin			
K310R [194,197,198]		Endometrial			
A314D [194]		Endometrial		PS [194]	
A315T [197]		Endometrial			
Q361R* [206]		Colon			
T370R [193]		Skin			
S372C [198]		Endometrial		BSS [204]	
Y375C [197,198]		Endometrial		BSS [204]	
Y375C [199]		Ovary			
I380V		Lung			
C382R [194,197,198]		Endometrial			
A389T [194]	Endometrial				
M391R [197]	Endometrial				
G462E [206]	Brain				
W474X [193]	Skin				
E475K [193]	Skin	Enhanced kinase activity but less stable [193]			
<u>D530N</u> [193]	Skin	Reduced kinase activity [193]			
H544Q [182] (SNP)	Lung				
I547V [197,198]	Endometrial				
<b>N549K</b> [194,197,198]	Endometrial	Enhanced kinase activity [194]			
E574K [193]	Skin				
P582L [206]	Colon				
R612T† [184,187]	Lung				
E636K [193]	Skin				
M640I [193]	Skin	Predicted to decrease kinase activity [193]			
I642V [193]	Skin	Reduced kinase activity [193]			
<u>A648T</u> [193]	Skin	Reduced kinase activity [193]	LADD[207]		

Table S2 Continued

Receptor	Mutation	Cancer type	Consequence	Syndrome
FGFR3	K659M [194]	Endometrial	Enhanced kinase activity [208]	CR [209]
	<b>K659N</b> [194]	Endometrial		
	K659E [197,198]	Endometrial		
	S688F [193]	Skin	Predicted to decrease kinase activity [193]	
	G701S [193]	Skin		
	P708S [193]	Skin		
	R759X/Q [193]	Skin	Predicted to impair phosphorylation of Tyr <sup>769</sup> [193]	
	L770V [193]	Skin		
	T79S [184]	Lung		
	G197S [171] (SNP)	MM	Mutation of analogous cysteine residue in FGFR2 causes PS [210]	
	C228R [184]	Colon		
	Y241C [159]	MM		
	<b>R248C</b> [121,211–227]	Bladder	Ligand-independent dimerization [229]	TDI [229]
	<b>R248C</b> [228]	Head and neck	Ligand-independent dimerization [229]	TDI [229]
	<b>R248C</b> [161,165]	MM		
	<b>S249C</b> [226,230,231]	Cervix		
	<b>S249C</b> [121,211–227,232–234]	Bladder	Ligand-independent dimerization [229]	TDI [229]
	<b>S249C</b> [235]	Head and neck		
	<b>S249C</b> [236]	Prostate		
	P250R [171] (SNP)	MM	Ligand-independent dimerization [229,237]	TDI [229,237]
	E322K [202]	Colon		
	<b>G370C</b> [121,211–215,217–219,221–227,234]	Bladder		
	<b>S371C</b> [121,211,213,214,217,220,227]	Bladder	Ligand-independent dimerization [229,237]	TDI [229,237]
	<b>Y373C</b> [121,211–224,227,232–234,238,239]	Bladder	Ligand-independent dimerization [229,237]	TDI [229,237]
	<b>Y373C</b> [169,170,240,241]	MM	Enhanced kinase activity [244]	ACH [245]
	I376C [214]	Bladder		
	<b>G380R</b> [121,211,213,214,242]	Bladder		
	<b>G380R</b> [243]	MM	Enhanced kinase activity [240]	
	<b>G382D</b> [240]	MM		
	F384L [211,213,220] (SNP)	Bladder		
	F384L [236]	Prostate	Stabilization of dimer [247]	CS [248]
	F384L/C [171,241,246]	MM		
	<b>A391E</b> [121,212,214,218,221,225]	Bladder		
<b>A391E</b> [236]	Prostate	Enhanced kinase activity [252,253]	TDII [253]	
S433C [171]	MM			
A441T [171] (SNP)	MM			
A452S [171] (SNP)	MM	Enhanced kinase activity [253]	HCH [253]	
E466K [249]	Brain			
D617G [228]	Head and neck			
V630M [228]	Head and neck	Enhanced kinase activity [253]	TDI, SADDAN [253]	
D646Y [250]	Bladder			
<b>K650E</b> [121,184,218–221,223,224,226,227,234,239]	Bladder			
<b>K650E</b> [251]	Testis	Enhanced kinase activity [253]	HCH [253]	
<b>K650E</b> [170,240,241]	MM			
<b>K650Q</b> [121,217,234]	Bladder			
<b>K650M</b> [212,215,218,219,221–223,227,242]	Bladder	Enhanced kinase activity [253]	AN [254]	
<b>K650M</b> [251]	Testis			
<b>K650M</b> [170,171,241]	MM			
<b>K650N</b> [251]	Testis	Enhanced kinase activity [255]	AN [254]	
<b>K650T</b> [218,221,222,242]	Bladder			
<b>K650T</b> [251]	Testis			
E686K [228]	Head and neck	Enhanced kinase activity [255]		
<b>G697C</b> [255]	Head and neck			
A717T [171] (SNP)	MM			
I726F [171] (SNP)	MM	Constitutive activation [256]	A common SNP that occurs in approximately 50 % of the population [268]	
C56S [35]	RMS			
R72L [35]	RMS			
T122A [35]	RMS	A common SNP that occurs in approximately 50 % of the population [268]		
A175T [35]	RMS			
R183S [182] (SNP)	Lung			
S232I [182] (SNP)	Lung	Constitutive activation [256]		
R234H [35]	RMS			
<b>Y367C</b> [183]	Breast			
G388R [257–259] (SNP)	Lung	A common SNP that occurs in approximately 50 % of the population [268]		
G388R [87]	Liver			
G388R [25,183,260,261]	Head and neck			
G388R [35]	RMS	Constitutive activation [256]		
G388R [262]	Soft tissue sarcoma			
G388R [183,263–267]	Prostate			

**Table S2 Continued**

Receptor	Mutation	Cancer type	Consequence	Syndrome
	G388R [268]	Colon		
	G388R [183,265,268]	Breast		
	G388R [183]	Brain		
	G388R [153,183]	Skin		
	G388R [269]	Stomach		
	N535D	RMS		
	<b>N535K</b> [35]	RMS	Enhanced kinase activity [35]	
	<b>V550E</b> [35]	RMS	Enhanced kinase activity [35]	
	V550L [35]	RMS		
	V550M‡ [184,185]	Breast		
	A554V [35]	RMS		
	G576D [35]	RMS		
	R616G [182] (SNP)	Lung		
	E681K [182,270] (SNP)	Lung		
	P712T‡ [184,187]	Lung		
	P716R [193]	Skin		
	A729G [182] (SNP)	Lung		
	S772N‡ [184]	Lung		

\*Glu<sup>361</sup> is only present in FGFR2 IIIb

†FGFR2 R612T is referred to as R496T in the literature due to a numbering relative to FGFR2 isoform 7 precursor which lacks two exons compared with transcript variant 1.

‡FGFR4 V550M, P712T and S772N are referred to as V510M, P672T and S732N (respectively) in the literature and in COSMIC due to a numbering relative to FGFR4 transcript variant 2, which lacks 40 amino acids (including the transmembrane domain) compared with X57205.

**Table S3 FGFR fusion proteins identified in human cancer**

Fusion proteins reported to display oncogenic properties in cell lines and mouse models are indicated in bold. L/EMS/L, Leukaemia/8p11 myeloproliferative disorder/Lymphoma; TKD, tyrosine kinase domain; RRM, RNA recognition motif; HLH, helix-loop-helix; LRR, leucine-rich repeat; CC, coiled coil; PDZ, PSD-95/Dlg/ZO-1.

Receptor	Fusion partner	Cancer/Disease	Oligomerization domain	Oncogenic potential
FGFR1	<b>ZNF198/RAMP/FIM/ZMYM2</b> [271–277]	L/EMS/L	Zinc finger	Yes [278–282]
	<b>FOP/FGFR10P1</b> [283–286]	L/EMS/L, lung	LRR	Yes [287,288]
	<b>CEP110/CEP1</b> [286,289–292]	L/EMS/L	Leucine zipper	Yes [290]
	<b>BCR</b> [278,293–296]	L/EMS/L	CC	Yes [278,281]
	LRRFIP1 [297]	L/EMS/L	CC	ND
	<b>FGFR10P2</b> [298,299]	L/EMS/L	CC	Yes [298]
	TRIM24/TIF1 [300]	L/EMS/L	CC	ND
	MYO18A [301]	L/EMS/L	PDZ? CC?	ND
	CPSF6 [302]	L/EMS/L	RRM?	ND
	HERV-K [303]	L/EMS/L		ND
	PLAG1 [304]	Head and neck		ND (fusion does not include TKD of FGFR)
	<b>CUX1</b> [305]	L/EMS/L		Yes [305]
	FGFR3	<b>TEL/ETV6</b> [306]	L/EMS/L	HLH

## REFERENCES

- 1 Yamaguchi, F., Saya, H., Bruner, J. M. and Morrison, R. S. (1994) Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. *Proc. Natl. Acad. Sci. U.S.A.* **91**, 484–488
- 2 Suzui, H., Takahashi, J. A., Fukumoto, M., Hashimoto, N., Itoh, N., Hatanaka, M. and Kikuchi, H. (1994) Immunohistochemical study for basic fibroblast growth factor and fibroblast growth factor receptor I in pituitary adenomas. *Neurosci. Lett.* **171**, 192–196
- 3 Ueba, T., Takahashi, J. A., Fukumoto, M., Ohta, M., Ito, N., Oda, Y., Kikuchi, H. and Hatanaka, M. (1994) Expression of fibroblast growth factor receptor-1 in human glioma and meningioma tissues. *Neurosurgery* **34**, 221–225
- 4 Morrison, R. S., Yamaguchi, F., Saya, H., Bruner, J. M., Yahanda, A. M., Donehower, L. A. and Berger, M. (1994) Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas. *J. Neurooncol.* **18**, 207–216
- 5 Allerstorfer, S., Sonvilla, G., Fischer, H., Spiegl-Kreinecker, S., Gaughofer, C., Setinek, U., Czech, T., Marosi, C., Buchroithner, J., Pichler, J. et al. (2008) FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities. *Oncogene* **27**, 4180–4190
- 6 Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* **455**, 1061–1068
- 7 Suzuki, T., Maruno, M., Wada, K., Kagawa, N., Fujimoto, Y., Hashimoto, N., Izumoto, S. and Yoshimine, T. (2004) Genetic analysis of human glioblastomas using a genomic microarray system. *Brain Tumor Pathol.* **21**, 27–34
- 8 Sasaki, T., Arai, H., Beppu, T. and Ogasawara, K. (2003) Detection of gene amplification and deletion in high-grade gliomas using a genome DNA microarray (GenoSensor Array 300). *Brain Tumor Pathol.* **20**, 59–63
- 9 Yamada, S. M., Yamada, S., Hayashi, Y., Takahashi, H., Teramoto, A. and Matsumoto, K. (2002) Fibroblast growth factor receptor (FGFR) 4 correlated with the malignancy of human astrocytomas. *Neurol. Res.* **24**, 244–248
- 10 Sugiura, K., Ozawa, S., Kitagawa, Y., Ueda, M. and Kitajima, M. (2007) Co-expression of aFGF and FGFR-1 is predictive of a poor prognosis in patients with esophageal squamous cell carcinoma. *Oncol. Rep.* **17**, 557–564
- 11 Douwes Dekker, P. B., Kuipers-Dijkshoorn, N. J., Baelde, H. J., van der Mey, A. G., Hogendoorn, P. C. and Cornelisse, C. J. (2007) Basic fibroblast growth factor and fibroblastic growth factor receptor-1 may contribute to head and neck paraganglioma development by an autocrine or paracrine mechanism. *Hum. Pathol.* **38**, 79–85
- 12 Freier, K., Schwaenen, C., Sticht, C., Flechtenmacher, C., Muhlring, J., Hofele, C., Radlwimmer, B., Lichter, P. and Joos, S. (2007) Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). *Oral Oncol.* **43**, 60–66
- 13 Hase, T., Kawashiri, S., Tanaka, A., Nozaki, S., Noguchi, N., Kato, K., Nakaya, H. and Nakagawa, K. (2006) Correlation of basic fibroblast growth factor expression with the invasion and the prognosis of oral squamous cell carcinoma. *J. Oral Pathol. Med.* **35**, 136–139
- 14 Ishizuka, T., Tanabe, C., Sakamoto, H., Aoyagi, K., Maekawa, M., Matsukura, N., Tokunaga, A., Tajiri, T., Yoshida, T., Terada, M. and Sasaki, H. (2002) Gene amplification profiling of esophageal squamous cell carcinomas by DNA array CGH. *Biochem. Biophys. Res. Commun.* **296**, 152–155
- 15 Myoken, Y., Myoken, Y., Okamoto, T., Sato, J. D., Kan, M., McKeenan, W. L., Nakahara, M. and Takada, K. (1996) Immunohistochemical study of overexpression of fibroblast growth factor-1 (FGF-1), FGF-2, and FGF receptor-1 in human malignant salivary gland tumours. *J. Pathol.* **178**, 429–436
- 16 Iida, S., Katoh, O., Tokunaga, A. and Terada, M. (1994) Expression of fibroblast growth factor gene family and its receptor gene family in the human upper gastrointestinal tract. *Biochem. Biophys. Res. Commun.* **199**, 1113–1119
- 17 Dellacono, F. R., Spiro, J., Eisma, R. and Kreutzer, D. (1997) Expression of basic fibroblast growth factor and its receptors by head and neck squamous carcinoma tumor and vascular endothelial cells. *Am. J. Surg.* **174**, 540–544
- 18 Yoshino, M., Ishiwata, T., Watanabe, M., Matsunobu, T., Komine, O., Ono, Y., Yamamoto, T., Fujii, T., Matsumoto, K., Tokunaga, A. and Naito, Z. (2007) Expression and roles of keratinocyte growth factor and its receptor in esophageal cancer cells. *Int. J. Oncol.* **31**, 721–728
- 19 Vairaktaris, E., Ragos, V., Yapijakis, C., Derka, S., Vassiliou, S., Nkenke, E., Yannopoulos, A., Spyridonidou, S., Vylliotis, A., Papakosta, V. et al. (2006) FGFR-2 and -3 play an important role in initial stages of oral oncogenesis. *Anticancer Res.* **26**, 4217–4221
- 20 Wakulich, C., Jackson-Boeters, L., Daley, T. D. and Wysocki, G. P. (2002) Immunohistochemical localization of growth factors fibroblast growth factor-1 and fibroblast growth factor-2 and receptors fibroblast growth factor receptor-2 and fibroblast growth factor receptor-3 in normal oral epithelium, epithelial dysplasias, and squamous cell carcinoma. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.* **93**, 573–579
- 21 Janot, F., el-Naggar, A. K., Morrison, R. S., Liu, T. J., Taylor, D. L. and Clayman, G. L. (1995) Expression of basic fibroblast growth factor in squamous cell carcinoma of the head and neck is associated with degree of histologic differentiation. *Int. J. Cancer* **64**, 117–123
- 22 Zhang, Y., Wang, H., Toratani, S., Sato, J. D., Kan, M., McKeenan, W. L. and Okamoto, T. (2001) Growth inhibition by keratinocyte growth factor receptor of human salivary adenocarcinoma cells through induction of differentiation and apoptosis. *Proc. Natl. Acad. Sci. U.S.A.* **98**, 11336–11340
- 23 Henson, B. J. and Gollin, S. M. (2010) Overexpression of KLF13 and FGFR3 in oral cancer cells. *Cytogenet. Genome Res.* **128**, 192–198
- 24 Vekony, H., Ylstra, B., Wiling, S. M., Meijer, G. A., van de Wiel, M. A., Leemans, C. R., Van der Waal, I. and Bloemena, E. (2007) DNA copy number gains at loci of growth factors and their receptors in salivary gland adenoid cystic carcinoma. *Clin. Cancer Res.* **13**, 3133–3139
- 25 Streit, S., Bange, J., Fichtner, A., Ihrlar, S., Issing, W. and Ullrich, A. (2004) Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. *Int. J. Cancer* **111**, 213–217
- 26 Schaefer, K. L., Wai, D. H., Poremba, C., Korsching, E., van Valen, F., Ozaki, T., Boecker, W. and Dockhorn-Dwornczak, B. (2002) Characterization of the malignant melanoma of soft-parts cell line GG-62 by expression analysis using DNA microarrays. *Virchows Arch.* **440**, 476–484
- 27 Bovee, J. V., van Den Broek, L. J., Cleton-Jansen, A. M. and Hogendoorn, P. C. (2000) Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma. *Lab. Invest.* **80**, 1925–1934
- 28 Baird, K., Davis, S., Antonescu, C. R., Harper, U. L., Walker, R. L., Chen, Y., Glatfelter, A. A., Duray, P. H. and Meltzer, P. S. (2005) Gene expression profiling of human sarcomas: insights into sarcoma biology. *Cancer Res.* **65**, 9226–9235
- 29 Missiaglia, E., Selfe, J., Hamdi, M., Williamson, D., Schaaf, G., Fang, C., Koster, J., Summersgill, B., Messahel, B., Versteeg, R. et al. (2009) Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development. *Genes Chromosomes Cancer* **48**, 455–467
- 30 Goldstein, M., Meller, I. and Orr-Urtreger, A. (2007) FGFR1 over-expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5' CpG island and abnormal expression of the AKT1, NOG, and BMP4 genes. *Genes Chromosomes Cancer* **46**, 1028–1038
- 31 Woolley, P. V., Gollin, S. M., Riskalla, W., Finkelstein, S., Stefanik, D. F., Riskalla, L., Swaney, W. P., Weisenthal, L. and McKenna, Jr, R. J. (2000) Cytogenetics, immunostaining for fibroblast growth factors, p53 sequencing, and clinical features of two cases of cystosarcoma phylloides. *Mol. Diagn.* **5**, 179–190
- 32 Cottoni, F., Ceccarelli, S., Masala, M. V., Montesu, M. A., Satta, R., Pirodda, C., Rotolo, S., Frati, L., Marchese, C. and Angeloni, A. (2009) Overexpression of the fibroblast growth factor receptor 2-IIIc in Kaposi's sarcoma. *J. Dermatol. Sci.* **53**, 65–68
- 33 Wachtel, M., Dettling, M., Koscielniak, E., Stegmaier, S., Treuner, J., Simon-Klingenstein, K., Buhlmann, P., Niggli, F. K. and Schaefer, B. W. (2004) Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. *Cancer Res.* **64**, 5539–5545
- 34 Hirotsu, M., Setoguchi, T., Matsunoshita, Y., Sasaki, H., Nagao, H., Gao, H., Sugimura, K. and Komiya, S. (2009) Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells. *Br. J. Cancer* **101**, 2030–2037
- 35 Taylor, IV, J. G., Cheuk, A. T., Tsang, P. S., Chung, J. Y., Song, Y. K., Desai, K., Yu, Y., Chen, Q. R., Shah, K., Youngblood, V. et al. (2009) Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. *J. Clin. Invest.* **119**, 3395–3407
- 36 Khan, J., Wei, J. S., Ringner, M., Saal, L. H., Ladanyi, M., Westermann, F., Berthold, F., Schwab, M., Antonescu, C. R., Peterson, C. and Meltzer, P. S. (2001) Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. *Nat. Med.* **7**, 673–679
- 37 Yu, S. J., Zheng, L., Ladanyi, M., Asa, S. L. and Ezzat, S. (2004) Sp1-mediated transcriptional control of fibroblast growth factor receptor 4 in sarcomas of skeletal muscle lineage. *Clin. Cancer Res.* **10**, 6750–6758
- 38 Schaaf, G. J., Ruijter, J. M., van Ruissen, F., Zwijnenburg, D. A., Waaijer, R., Valentijn, L. J., Benit-Deekman, J., van Kampen, A. H., Baas, F. and Kool, M. (2005) Full transcriptome analysis of rhabdomyosarcoma, normal, and fetal skeletal muscle: statistical comparison of multiple SAGE libraries. *FASEB J.* **19**, 404–406
- 39 Davicioni, E., Finckenstein, F. G., Shabazzian, V., Buckley, J. D., Triche, T. J. and Anderson, M. J. (2006) Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. *Cancer Res.* **66**, 6936–6946
- 40 St Bernard, R., Zheng, L., Liu, W., Winer, D., Asa, S. L. and Ezzat, S. (2005) Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. *Endocrinology* **146**, 1145–1153
- 41 Shingu, K., Fujimori, M., Ito, K., Hama, Y., Kasuga, Y., Kobayashi, S., Itoh, N. and Amano, J. (1998) Expression of fibroblast growth factor-2 and fibroblast growth factor receptor-1 in thyroid diseases: difference between neoplasms and hyperplastic lesions. *Endocr. J.* **45**, 35–43

- 42 Arora, N., Scognamiglio, T., Lubitz, C. C., Moo, T. A., Kato, M. A., Zhu, B., Zarnegar, R., Chen, Y. T. and Fahey, III, T. J. (2009) Identification of borderline thyroid tumors by gene expression array analysis. *Cancer* **115**, 5421–5431
- 43 Donnem, T., Al-Shibli, K., Al-Saad, S., Busund, L. T. and Bremnes, R. M. (2009) Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival. *J. Thorac. Oncol.* **4**, 578–585
- 44 Weiss, J., Sos, M. L., Seidel, D., Peifer, M., Zander, T., Heuckmann, J. M., Ullrich, R. T., Menon, R., Maier, S., Soltermann, A. et al. (2010) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. *Sci. Transl. Med.* **2**, 62ra93
- 45 Berger, W., Setinek, U., Mohr, T., Kindas-Mugge, I., Vetterlein, M., Dekan, G., Eckersberger, F., Caldas, C. and Micksche, M. (1999) Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells. *Int. J. Cancer* **83**, 415–423
- 46 Fischer, H., Taylor, N., Allerstorfer, S., Grusch, M., Sonvilla, G., Holzmann, K., Setinek, U., Elbling, L., Cantonati, H., Grasl-Kraupp, B. et al. (2008) Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. *Mol. Cancer Ther.* **7**, 3408–3419
- 47 Marek, L., Ware, K. E., Fritzsche, A., Hercule, P., Helton, W. R., Smith, J. E., McDermott, L. A., Coldren, C. D., Nemenoff, R. A., Merrick, D. T. et al. (2009) Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. *Mol. Pharmacol.* **75**, 196–207
- 48 Behrens, C., Lin, H. Y., Lee, J. J., Raso, M. G., Hong, W. K., Wistuba, I. I. and Lotan, R. (2008) Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. *Clin. Cancer Res.* **14**, 6014–6022
- 49 Zhao, X., Weir, B. A., LaFramboise, T., Lin, M., Beroukhi, R., Garraway, L., Beheshti, J., Lee, J. C., Naoki, K., Richards, W. G. et al. (2005) Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. *Cancer Res.* **65**, 5561–5570
- 50 Guddo, F., Fontanini, G., Reina, C., Vignola, A. M., Angeletti, A. and Bonsignore, G. (1999) The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression. *Hum. Pathol.* **30**, 788–794
- 51 Volm, M., Koomagi, R., Mattern, J. and Stammers, G. (1997) Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas. *Eur. J. Cancer* **33**, 691–693
- 52 Takamami, I., Tanaka, F., Hashizume, T., Kikuchi, K., Yamamoto, Y., Yamamoto, T. and Kodaira, S. (1996) The basic fibroblast growth factor and its receptor in pulmonary adenocarcinomas: an investigation of their expression as prognostic markers. *Eur. J. Cancer* **32A**, 1504–1509
- 53 Bass, A. J., Watanabe, H., Mermel, C. H., Yu, S., Perner, S., Verhaak, R. G., Kim, S. Y., Wardwell, L., Tamayo, P., Gat-Viks, I. et al. (2009) SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. *Nat. Genet.* **41**, 1238–1242
- 54 Giatromanolaki, A., Koukourakis, M. I., Sivridis, E., O'Byrne, K., Cox, G., Thorpe, P. E., Gatter, K. C. and Harris, A. L. (2000) Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. *Clin. Cancer Res.* **6**, 1917–1921
- 55 Levina, V., Marrangoni, A. M., DeMarco, R., Gorelik, E. and Lokshin, A. E. (2008) Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. *PLoS ONE* **3**, e3077
- 56 Yamayoshi, T., Nagayasu, T., Matsumoto, K., Abo, T., Hishikawa, Y. and Koji, T. (2004) Expression of keratinocyte growth factor/fibroblast growth factor-7 and its receptor in human lung cancer: correlation with tumour proliferative activity and patient prognosis. *J. Pathol.* **204**, 110–118
- 57 Woenckhaus, M., Klein-Hitpass, L., Grepmeier, U., Merk, J., Pfeifer, M., Wild, P., Bettstetter, M., Wuensch, P., Blaszyk, H., Hartmann, A. et al. (2006) Smoking and cancer-related gene expression in bronchial epithelium and non-small-cell lung cancers. *J. Pathol.* **210**, 192–204
- 58 Ohira, T., Akutagawa, S., Usuda, J., Nakamura, T., Hirano, T., Tsuboi, M., Nishio, K., Taguchi, F., Ikeda, N., Nakamura, H. et al. (2002) Up-regulated gene expression of angiogenesis factors in post-chemotherapeutic lung cancer tissues determined by cDNA microarray. *Oncol. Rep.* **9**, 723–728
- 59 Nakamura, N., Iijima, T., Mase, K., Furuya, S., Kano, J., Morishita, Y. and Noguchi, M. (2004) Phenotypic differences of proliferating fibroblasts in the stroma of lung adenocarcinoma and normal bronchus tissue. *Cancer Sci.* **95**, 226–232
- 60 Kadota, M., Sato, M., Duncan, B., Ooshima, A., Yang, H. H., Diaz-Meyer, N., Gere, S., Kageyama, S., Fukuoka, J., Nagata, T., Tsukada, K. et al. (2009) Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. *Cancer Res.* **69**, 7357–7365
- 61 Gruel, N., Lucchesi, C., Raynal, V., Rodrigues, M. J., Pierron, G., Goudefroye, R., Cottu, P., Reyat, F., Sastre-Garau, X., Fourquet, A. et al. (2010) Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma. *Eur. J. Cancer* **46**, 2399–2407
- 62 Turner, N., Pearson, A., Sharpe, R., Lambros, M., Geyer, F., Lopez-Garcia, M. A., Natrajan, R., Marchio, C., Iorns, E., Mackay, A. et al. (2010) FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. *Cancer Res.* **70**, 2085–2094
- 63 Elbauomy, E. S., Green, A. R., Lambros, M. B., Turner, N. C., Grainge, M. J., Powe, D., Ellis, I. O. and Reis-Filho, J. S. (2007) FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. *Breast Cancer Res.* **9**, R23
- 64 Courjal, F., Cuny, M., Simony-Lafontaine, J., Louason, G., Speiser, P., Zeillinger, R., Rodriguez, C. and Theillet, C. (1997) Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. *Cancer Res.* **57**, 4360–4367
- 65 Letessier, A., Sircoulomb, F., Ginestier, C., Cervera, N., Monville, F., Gelsi-Boyer, V., Esterni, B., Geneix, J., Finetti, P., Zemmour, C. et al. (2006) Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. *BMC Cancer* **6**, 245
- 66 Jacquemier, J., Adelaide, J., Parc, P., Penault-Llorca, F., Planché, J., deLapeyrière, O. and Birnbaum, D. (1994) Expression of the FGFR1 gene in human breast-carcinoma cells. *Int. J. Cancer* **59**, 373–378
- 67 Theillet, C., Adelaide, J., Louason, G., Bonnet-Dorion, F., Jacquemier, J., Adnane, J., Longy, M., Katsaros, D., Sisoni, P. and Gaudray, P. (1993) FGFR1 and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. *Genes Chromosomes Cancer* **7**, 219–226
- 68 Reis-Filho, J. S., Simpson, P. T., Turner, N. C., Lambros, M. B., Jones, C., Mackay, A., Grigoriadis, A., Sarrio, D., Savage, K., Dexter, T. et al. (2006) FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. *Clin. Cancer Res.* **12**, 6652–6662
- 69 Andre, F., Job, B., Dessen, P., Tordai, A., Michiels, S., Liedtke, C., Richon, C., Yan, K., Wang, B., Vassal, G. et al. (2009) Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. *Clin. Cancer Res.* **15**, 441–451
- 70 Kwek, S. S., Roy, R., Zhou, H., Climent, J., Martinez-Climent, J. A., Fridlyand, J. and Albertson, D. G. (2009) Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis. *Oncogene* **28**, 1892–1903
- 71 Gelsi-Boyer, V., Orsetti, B., Cervera, N., Finetti, P., Sircoulomb, F., Rouge, C., Lasorsa, L., Letessier, A., Ginestier, C., Monville, F. et al. (2005) Comprehensive profiling of 8p11-12 amplification in breast cancer. *Mol. Cancer Res.* **3**, 655–667
- 72 Chin, K., DeVries, S., Fridlyand, J., Spellman, P. T., Roydasgupta, R., Kuo, W. L., Lapuk, A., Neve, R. M., Qian, Z., Ryder, T. et al. (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiology. *Cancer Cell* **10**, 529–541
- 73 Adnane, J., Gaudray, P., Dionne, C. A., Crumley, G., Jaye, M., Schlessinger, J., Jeanteur, P., Birnbaum, D. and Theillet, C. (1991) BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. *Oncogene* **6**, 659–663
- 74 Penault-Llorca, F., Bertucci, F., Adelaide, J., Parc, P., Coulier, F., Jacquemier, J., Birnbaum, D. and deLapeyrière, O. (1995) Expression of FGF and FGF receptor genes in human breast cancer. *Int. J. Cancer* **61**, 170–176
- 75 Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J. P., Tong, F. et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. *Cancer Cell* **10**, 515–527
- 76 Forozan, F., Veldman, R., Ammerman, C. A., Parsa, N. Z., Kallioniemi, A., Kallioniemi, O. P. and Ethier, S. P. (1999) Molecular cytogenetic analysis of 11 new breast cancer cell lines. *Br. J. Cancer* **81**, 1328–1334
- 77 Adelaide, J., Finetti, P., Bekhouche, I., Repellini, L., Geneix, J., Sircoulomb, F., Charafe-Jauffret, E., Cervera, N., Desplans, J., Parzy, D. et al. (2007) Integrated profiling of basal and luminal breast cancers. *Cancer Res.* **67**, 11565–11575
- 78 Heiskanen, M., Kononen, J., Barlund, M., Torhorst, J., Sauter, G., Kallioniemi, A. and Kallioniemi, O. (2001) CGH, cDNA and tissue microarray analyses implicate FGFR2 amplification in a small subset of breast tumors. *Anal. Cell. Pathol.* **22**, 229–234
- 79 Turner, N., Lambros, M. B., Horlings, H. M., Pearson, A., Sharpe, R., Natrajan, R., Geyer, F. C., van Kouwenhove, M., Kreike, B. and Mackay, A. (2010) Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. *Oncogene* **29**, 2013–2023
- 80 Kuroso, K., Imai, Y., Kobayashi, M., Yanagimoto, K., Suzuki, T., Kojima, M. and Ueda, Y. (2010) Immunohistochemical detection of fibroblast growth factor receptor 3 in human breast cancer: correlation with clinicopathological/molecular parameters and prognosis. *Pathobiology* **77**, 231–240
- 81 Roidl, A., Berger, H. J., Kumar, S., Bange, J., Knyazev, P. and Ullrich, A. (2009) Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. *Clin. Cancer Res.* **15**, 2058–2066

- 82 Jaakkola, S., Salmikangas, P., Nylund, S., Partanen, J., Armstrong, E., Pyrhonen, S., Lehtovirta, P. and Nevanlinna, H. (1993) Amplification of *fgfr4* gene in human breast and gynecological cancers. *Int. J. Cancer* **54**, 378–382
- 83 Kin, M., Sata, M., Ueno, T., Torimura, T., Inuzuka, S., Tsuji, R., Sujaku, K., Sakamoto, M., Sugawara, H., Tamaki, S. and Tanikawa, K. (1997) Basic fibroblast growth factor regulates proliferation and motility of human hepatoma cells by an autocrine mechanism. *J. Hepatol.* **27**, 677–687
- 84 Gauglhofer, C., Sagmeister, S., Schrottmair, W., Fischer, C., Rodgarkia-Dara, C., Mohr, T., Stattner, S., Bichler, C., Kandioler, D., Wrba, F. et al. (2010) Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. *Hepatology* **53**, 854–864
- 85 Amann, T., Bataille, F., Spruss, T., Dettmer, K., Wild, P., Liedtke, C., Muhlbauer, M., Kiefer, P., Oefner, P. J., Trautwein, C. et al. (2010) Reduced expression of fibroblast growth factor receptor 2/IIIb in hepatocellular carcinoma induces a more aggressive growth. *Am. J. Pathol.* **176**, 1433–1442
- 86 Qiu, W. H., Zhou, B. S., Chu, P. G., Chen, W. G., Chung, C., Shih, J., Hwu, P., Yeh, C., Lopez, R. and Yen, Y. (2005) Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma. *World J. Gastroenterol.* **11**, 5266–5272
- 87 Ho, H. K., Pok, S., Streit, S., Ruhe, J. E., Hart, S., Lim, K. S., Loo, H. L., Aung, M. O., Lim, S. G. and Ullrich, A. (2009) Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. *J. Hepatol.* **50**, 118–127
- 88 Tsou, A. P., Wu, K. M., Tsen, T. Y., Chi, C. W., Chiu, J. H., Lui, W. Y., Hu, C. P., Chang, C., Chou, C. K. and Tsai, S. F. (1998) Parallel hybridization analysis of multiple protein kinase genes: identification of gene expression patterns characteristic of human hepatocellular carcinoma. *Genomics* **50**, 331–340
- 89 Kornmann, M., Ishiwata, T., Matsuda, K., Lopez, M. E., Fukahi, K., Asano, G., Beger, H. G. and Korc, M. (2002) Il1c isoform of fibroblast growth factor receptor 1 is overexpressed in human pancreatic cancer and enhances tumorigenicity of hamster ductal cells. *Gastroenterology* **123**, 301–313
- 90 Motoda, N., Matsuda, Y., Onda, M., Ishiwata, T., Uchida, E. and Naito, Z. (2011) Overexpression of fibroblast growth factor receptor 4 in high-grade pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. *Int. J. Oncol.* **38**, 133–143
- 91 Liu, Z., Ishiwata, T., Zhou, S., Maier, S., Henne-Bruns, D., Korc, M., Bachem, M. and Kornmann, M. (2007) Human fibroblast growth factor receptor 1-IIIb is a functional fibroblast growth factor receptor expressed in the pancreas and involved in proliferation and movement of fibroblast ductal cells. *Pancreas* **35**, 147–157
- 92 Leung, H. Y., Gullick, W. J. and Lemoine, N. R. (1994) Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer. *Int. J. Cancer* **59**, 667–675
- 93 Kobrin, M. S., Yamanaka, Y., Friess, H., Lopez, M. E. and Korc, M. (1993) Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. *Cancer Res.* **53**, 4741–4744
- 94 Nomura, S., Yoshitomi, H., Takano, S., Shida, T., Kobayashi, S., Ohtsuka, M., Kimura, F., Shimizu, H., Yoshidome, H., Kato, A. and Miyazaki, M. (2008) FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer. *Br. J. Cancer* **99**, 305–313
- 95 Cho, K., Ishiwata, T., Uchida, E., Nakazawa, N., Korc, M., Naito, Z. and Tajiri, T. (2007) Enhanced expression of keratinocyte growth factor and its receptor correlates with venous invasion in pancreatic cancer. *Am. J. Pathol.* **170**, 1964–1974
- 96 Ishiwata, T., Friess, H., Buchler, M. W., Lopez, M. E. and Korc, M. (1998) Characterization of keratinocyte growth factor and receptor expression in human pancreatic cancer. *Am. J. Pathol.* **153**, 213–222
- 97 Shah, R. N., Ibbitt, J. C., Alitalo, K. and Hurst, H. C. (2002) FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1alpha. *Oncogene* **21**, 8251–8261
- 98 Shin, E. Y., Lee, B. H., Yang, J. H., Shin, K. S., Lee, G. K., Yun, H. Y., Song, Y. J., Park, S. C. and Kim, E. G. (2000) Up-regulation and co-expression of fibroblast growth factor receptors in human gastric cancer. *J. Cancer Res. Clin. Oncol.* **126**, 519–528
- 99 Gong, J., Morishita, A., Kurokouchi, K., Tani, J., Kato, K., Miyoshi, H., Inoue, H., Kobayashi, M., Liu, S., Murota, M. et al. (2010) Use of protein array to investigate receptor tyrosine kinases activated in gastric cancer. *Int. J. Oncol.* **36**, 101–106
- 100 Hattori, Y., Itoh, H., Uchino, S., Hosokawa, K., Ochiai, A., Ino, Y., Ishii, H., Sakamoto, H., Yamaguchi, N., Yanagihara, K. et al. (1996) Immunohistochemical detection of K-sam protein in stomach cancer. *Clin. Cancer Res.* **2**, 1373–1381
- 101 Kim, H. K., Choi, I. J., Kim, C. G., Kim, H. S., Oshima, A., Yamada, Y., Arai, T., Nishio, K., Michalowski, A. and Green, J. E. (2010) Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy. *Pharmacogenomics*. J., doi:10.1038/tpj.2010.87
- 102 Hara, T., Ooi, A., Kobayashi, M., Mai, M., Yanagihara, K. and Nakanishi, I. (1998) Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. *Lab. Invest.* **78**, 1143–1153
- 103 Peng, D. F., Sugihara, H., Mukaisho, K., Tsubosa, Y. and Hattori, T. (2003) Alterations of chromosomal copy number during progression of diffuse-type gastric carcinomas: metaphase- and array-based comparative genomic hybridization analyses of multiple samples from individual tumours. *J. Pathol.* **201**, 439–450
- 104 Matsunobu, T., Ishiwata, T., Yoshino, M., Watanabe, M., Kudo, M., Matsumoto, K., Tokunaga, A., Tajiri, T. and Naito, Z. (2006) Expression of keratinocyte growth factor receptor correlates with expansive growth and early stage of gastric cancer. *Int. J. Oncol.* **28**, 307–314
- 105 Tsujimoto, H., Sugihara, H., Hagiwara, A. and Hattori, T. (1997) Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer. *Virchows Arch.* **431**, 383–389
- 106 Yoshida, T., Sakamoto, H. and Terada, M. (1993) Amplified genes in cancer in upper digestive tract. *Semin. Cancer Biol.* **4**, 33–40
- 107 Mor, O., Ranzani, G. N., Ravia, Y., Rotman, G., Gutman, M., Manor, A., Amadori, D., Houldsworth, J., Hollstein, M., Schwab, M. and Shiloh, Y. (1993) DNA amplification in human gastric carcinomas. *Cancer Genet. Cytogenet.* **65**, 111–114
- 108 Toyokawa, T., Yashiro, M. and Hirakawa, K. (2009) Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma. *Oncol. Rep.* **21**, 875–880
- 109 Ueki, T., Koji, T., Tamiya, S., Nakane, P. K. and Tsuneyoshi, M. (1995) Expression of basic fibroblast growth factor and fibroblast growth factor receptor in advanced gastric carcinoma. *J. Pathol.* **177**, 353–361
- 110 Kunii, K., Davis, L., Gorenstein, J., Hatch, H., Yashiro, M., Di, B. A., Elbi, C. and Lutterbach, B. (2008) FGFR2-amplified gastric cancer cell lines require FGFR2 and ErbB3 signaling for growth and survival. *Cancer Res.* **68**, 2340–2348
- 111 Mazoni, D., Lorenzi, T., Mazzucchelli, R., Capparuccia, L., Morroni, M., Fiorini, R., Bracalenti, C., Catalano, A., David, G., Castellucci, M. et al. (2009) Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer. *Int. J. Immunopathol. Pharmacol.* **22**, 627–638
- 112 De Boer, W. I., Houtsmuller, A. B., Izadifar, V., Muscatelli-Groux, B., Van der Kwast, T. H. and Chopin, D. K. (1997) Expression and functions of EGF, FGF and TGFbeta-growth-factor family members and their receptors in invasive human transitional-cell-carcinoma cells. *Int. J. Cancer* **71**, 284–291
- 113 Simon, R., Richter, J., Wagner, U., Fijan, A., Bruderer, J., Schmid, U., Ackermann, D., Maurer, R., Alund, G., Knomagel, H. et al. (2001) High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. *J. Cancer Res.* **61**, 4514–4519
- 114 Veltman, J. A., Fridlyand, J., Pejavar, S., Olshen, A. B., Korkola, J. E., DeVries, S., Carroll, P., Kuo, W. L., Pinkel, D., Albertson, D. et al. (2003) Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. *Cancer Res.* **63**, 2872–2880
- 115 Tomlinson, D. C., Lamont, F. R., Shnyder, S. D. and Knowles, M. A. (2009) Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. *Cancer Res.* **69**, 4613–4620
- 116 Diez de Medina, S. G., Chopin, D., El Marjou, A., Delouee, A., LaRochelle, W. J., Hoznek, A., Abbou, C., Aaronson, S. A., Thiery, J. P. and Radvanyi, F. (1997) Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas. *Oncogene* **14**, 323–330
- 117 Nord, H., Segersten, U., Sandgren, J., Wester, K., Busch, C., Menzel, U., Komorowski, J., Dumanski, J. P., Malmstrom, P. U. and de Stahl, T. D. (2010) Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma. *Int. J. Cancer* **126**, 1390–1402
- 118 Romanenko, A. M., Morimura, K., Kinoshita, A., Wanibuchi, H., Takahashi, S., Zamarin, W. K., Vinnichenko, W. I., Vozianov, A. F. and Fukushima, S. (2006) Upregulation of fibroblast growth factor receptor 3 and epidermal growth factor receptors, in association with Raf-1, in urothelial dysplasia and carcinoma in situ after the Chernobyl accident. *Cancer Sci.* **97**, 1168–1174
- 119 Mhaweche-Fauceglia, P., Fischer, G., Alvarez, Jr, V., Ahmed, A. and Herrmann, F. R. (2007) Predicting outcome in minimally invasive (T1a and T1b) urothelial bladder carcinoma using a panel of biomarkers: a high throughput tissue microarray analysis. *BJU Int.* **100**, 1182–1187
- 120 Gomez-Roman, J. J., Saenz, P., Molina, M., Cuevas, G. J., Escudero, K., Santa, C. S., Junquera, C., Simon, L., Martinez, A., Gutierrez Banos, J. L. et al. (2005) Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. *Clin. Cancer Res.* **11**, 459–465
- 121 Tomlinson, D. C., Baldo, O., Harnden, P. and Knowles, M. A. (2007) FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. *J. Pathol.* **213**, 91–98
- 122 Murphy, T., Darby, S., Mathers, M. E. and Gnanapragasam, V. J. (2009) Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype. *J. Pathol.* **220**, 452–460
- 123 Sahadevan, K., Darby, S., Leung, H. Y., Mathers, M. E., Robson, C. N. and Gnanapragasam, V. J. (2007) Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. *J. Pathol.* **213**, 82–90

- 124 Devilard, E., Bladou, F., Ramuz, O., Karsenty, G., Dales, J. P., Gravis, G., Nguyen, C., Bertucci, F., Xerri, L. and Birnbaum, D. (2006) FGFR1 and WT1 are markers of human prostate cancer progression. *BMC Cancer* **6**, 272
- 125 Gravdal, K., Halvorsen, O. J., Haukaas, S. A. and Akslen, L. A. (2006) Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer. *Virchows Arch.* **448**, 68–74
- 126 Edwards, J., Krishna, N. S., Witton, C. J. and Bartlett, J. M. (2003) Gene amplifications associated with the development of hormone-resistant prostate cancer. *Clin. Cancer Res.* **9**, 5271–5281
- 127 Valve, E. M., Nevalainen, M. T., Nurmi, M. J., Laato, M. K., Martikainen, P. M. and Harkonen, P. L. (2001) Increased expression of FGF-8 isoforms and FGF receptors in human premalignant prostatic intraepithelial neoplasia lesions and prostate cancer. *Lab. Invest.* **81**, 815–826
- 128 Giri, D., Ropiquet, F. and Iltmann, M. (1999) Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. *Clin. Cancer Res.* **5**, 1063–1071
- 129 Leung, H. Y., Mehta, P., Gray, L. B., Collins, A. T., Robson, C. N. and Neal, D. E. (1997) Keratinocyte growth factor expression in hormone insensitive prostate cancer. *Oncogene* **15**, 1115–1120
- 130 Hamaguchi, A., Toyama, I., Yoshiki, T. and Kimura, H. (1995) Demonstration of fibroblast growth factor receptor-1 in human prostate by polymerase chain reaction and immunohistochemistry. *Prostate* **27**, 141–147
- 131 Naimi, B., Latil, A., Fournier, G., Mangin, P., Cussenot, O. and Berthon, P. (2002) Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. *Prostate* **52**, 245–252
- 132 Gowardhan, B., Douglas, D. A., Mathers, M. E., McKie, A. B., McCracken, S. R., Robson, C. N. and Leung, H. Y. (2005) Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. *Br. J. Cancer* **92**, 320–327
- 133 Ropiquet, F., Giri, D., Kwabi-Addo, B., Mansukhani, A. and Iltmann, M. (2000) Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer. *Cancer Res.* **60**, 4245–4250
- 134 Suzuki, K., Tokue, A., Kamiakito, T., Kuriki, K., Saito, K. and Tanaka, A. (2001) Predominant expression of fibroblast growth factor (FGF) 8, FGF4, and FGF receptor 1 in nonseminomatous and highly proliferative components of testicular germ cell tumors. *Virchows Arch.* **439**, 616–621
- 135 Jang, J. H. (2005) Reciprocal relationship in gene expression between FGFR1 and FGFR3: implication for tumorigenesis. *Oncogene* **24**, 945–948
- 136 Jayson, G. C., Vives, C., Paraskova, C., Schofield, K., Coutts, J., Fleetwood, A. and Gallagher, J. T. (1999) Coordinated modulation of the fibroblast growth factor dual receptor mechanism during transformation from human colon adenoma to carcinoma. *Int. J. Cancer* **82**, 298–304
- 137 Sonvilla, G., Allerstorfer, S., Heinze, C., Stattner, S., Karner, J., Klimpfner, M., Wrba, F., Fischer, H., Gaughofer, C., Spiegl-Kreinecker, S. et al. (2010) Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration. *Br. J. Cancer* **102**, 1145–1156
- 138 O'Toole, S. A., Dunn, E., Sheppard, B. L., Klocker, H., Bektic, J., Smyth, P., Martin, C., Sheils, O. and O'Leary, J. J. (2006) Genome-wide analysis of deoxyribonucleic acid in endometrial cancer using comparative genomic hybridization microarrays. *Int. J. Gynecol. Cancer* **16**, 834–842
- 139 Mayr, D., Kanitz, V., Anderegg, B., Luthardt, B., Engel, J., Lohrs, U., Amann, G. and Diebold, J. (2006) Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays. *Am. J. Clin. Pathol.* **126**, 101–109
- 140 Ishikawa, A., Kudo, M., Nakazawa, N., Onda, M., Ishiwata, T., Takeshita, T. and Naito, Z. (2008) Expression of keratinocyte growth factor and its receptor in human endometrial cancer in cooperation with steroid hormones. *Int. J. Oncol.* **32**, 565–574
- 141 Visco, V., Carico, E., Marchese, C., Torrìsi, M. R., Frati, L., Vecchione, A. and Muraro, R. (1999) Expression of keratinocyte growth factor receptor compared with that of epidermal growth factor receptor and erbB-2 in endometrial adenocarcinoma. *Int. J. Oncol.* **15**, 431–435
- 142 Siegfried, S., Pekonen, F., Nyman, T., Ammala, M. and Rutanen, E. M. (1997) Distinct patterns of expression of keratinocyte growth factor and its receptor in endometrial carcinoma. *Cancer* **79**, 1166–1171
- 143 Gorringer, K. L., Jacobs, S., Thompson, E. R., Sridhar, A., Qiu, W., Choong, D. Y. and Campbell, I. G. (2007) High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. *Clin. Cancer Res.* **13**, 4731–4739
- 144 Crickard, K., Gross, J. L., Crickard, U., Yoonessi, M., Lele, S., Herblin, W. F. and Eidsvoog, K. (1994) Basic fibroblast growth factor and receptor expression in human ovarian cancer. *Gynecol. Oncol.* **55**, 277–284
- 145 Steele, I. A., Edmondson, R. J., Bulmer, J. N., Bolger, B. S., Leung, H. Y. and Davies, B. R. (2001) Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. *Oncogene* **20**, 5878–5887
- 146 Kurban, G., Ishiwata, T., Kudo, M., Yokoyama, M., Sugisaki, Y. and Naito, Z. (2004) Expression of keratinocyte growth factor receptor (KGFR/FGFR2 IIIb) in human uterine cervical cancer. *Oncol. Rep.* **11**, 987–991
- 147 Kawase, R., Ishiwata, T., Matsuda, Y., Onda, M., Kudo, M., Takeshita, T. and Naito, Z. (2010) Expression of fibroblast growth factor receptor 2 IIIc in human uterine cervical intraepithelial neoplasia and cervical cancer. *Int. J. Oncol.* **36**, 331–340
- 148 Hudelist, G., Czerwenka, K., Singer, C., Pischinger, K., Kubista, E. and Manavi, M. (2005) cDNA array analysis of cytobrush-collected normal and malignant cervical epithelial cells: a feasibility study. *Cancer Genet. Cytogenet.* **158**, 35–42
- 149 Straume, O. and Akslen, L. A. (2002) Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression. *Am. J. Pathol.* **160**, 1009–1019
- 150 Xerri, L., Battyani, Z., Grob, J. J., Parc, P., Hassoun, J., Bonerandi, J. J. and Birnbaum, D. (1996) Expression of FGF1 and FGFR1 in human melanoma tissues. *Melanoma Res.* **6**, 223–230
- 151 Hida, Y., Kubo, Y., Nishio, Y., Murakami, S., Fukumoto, D., Sayama, K., Hashimoto, K. and Arase, S. (2009) Malignant acanthosis nigricans with enhanced expression of fibroblast growth factor receptor 3. *Acta Derm. Venereol.* **89**, 435–437
- 152 Hida, Y., Kubo, Y. and Arase, S. (2009) Activation of fibroblast growth factor receptor 3 and oncogene-induced senescence in skin tumours. *Br. J. Dermatol.* **160**, 1258–1263
- 153 Streit, S., Mestel, D. S., Schmidt, M., Ullrich, A. and Berking, C. (2006) FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. *Br. J. Cancer* **94**, 1879–1886
- 154 Otsuki, T., Yamada, O., Yata, K., Sakaguchi, H., Kurebayashi, J., Nakazawa, N., Taniwaki, M., Yawata, Y. and Ueki, A. (1999) Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32.3) and FGFR3 translocation. *Int. J. Oncol.* **15**, 1205–1212
- 155 Chandesaris, M. O., Soulier, J., Labaune, S., Criquette, A., Repellini, L., Chemin, K., Malphettes, M., Fieschi, C., Asli, B., Uzunhan, Y. et al. (2007) Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma. *Br. J. Haematol.* **136**, 609–614
- 156 Krejci, P., Mekikian, P. B. and Wilcox, W. R. (2006) The fibroblast growth factors in multiple myeloma. *Leukemia* **20**, 1165–1168
- 157 Chang, H., Stewart, A. K., Qi, X. Y., Li, Z. H., Yi, Q. L. and Trudel, S. (2005) Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. *Blood* **106**, 353–355
- 158 Fabris, S., Agnelli, L., Mattioli, M., Baldini, L., Ronchetti, D., Morabito, F., Verdelli, D., Nobili, L., Intini, D., Callea, V. et al. (2005) Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses. *Genes Chromosomes Cancer* **42**, 117–127
- 159 Onwuazor, O. N., Wen, X. Y., Wang, D. Y., Zhuang, L., Masih-Khan, E., Claudio, J., Barlogie, B., Shaughnessy, Jr, J. D. and Stewart, A. K. (2003) Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. *Blood* **102**, 772–773
- 160 Keats, J. J., Reiman, T., Maxwell, C. A., Taylor, B. J., Larratt, L. M., Mant, M. J., Belch, A. R. and Pilarski, L. M. (2003) In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. *Blood* **101**, 1520–1529
- 161 Soverini, S., Terragna, C., Testoni, N., Ruggeri, D., Tosi, P., Zamagni, E., Cellini, C., Cavo, M., Baccarani, M., Tura, S. and Martinelli, G. (2002) Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis. *Haematologica* **87**, 1036–1040
- 162 Sibley, K., Fenton, J. A., Dring, A. M., Ashcroft, A. J., Rawstron, A. C. and Morgan, G. J. (2002) A molecular study of the t(4;14) in multiple myeloma. *Br. J. Haematol.* **118**, 514–520
- 163 Rasmussen, T., Hudlebusch, H. R., Knudsen, L. M. and Johnsen, H. E. (2002) FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance. *Br. J. Haematol.* **117**, 626–628
- 164 Zhan, F., Hardin, J., Kordsmeier, B., Bumm, K., Zheng, M., Tian, E., Sanderson, R., Yang, Y., Wilson, C., Zangari, M. et al. (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. *Blood* **99**, 1745–1757
- 165 Intini, D., Baldini, L., Fabris, S., Lombardi, L., Ciceri, G., Maiolo, A. T. and Neri, A. (2001) Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). *Br. J. Haematol.* **114**, 362–364
- 166 Ho, P. J., Brown, R. D., Pelka, G. J., Basten, A., Gibson, J. and Joshua, D. E. (2001) Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival. *Blood* **97**, 490–495



- 167 Nakazawa, N., Nishida, K., Tamura, A., Kobayashi, M., Iwai, T., Horieki, S., Nishigaki, H., Otsuki, T., Tomiyama, Y., Fujii, H. et al. (2000) Interphase detection of t(4;14)(p16.3;q32.3) by in situ hybridization and FGFR3 overexpression in plasma cell malignancies. *Cancer Genet. Cytogenet.* **117**, 89–96
- 168 Avet-Loiseau, H., Li, J. Y., Facon, T., Brigaudeau, C., Morineau, N., Maloisel, F., Rapp, M. J., Talmant, P., Trimoulet, F., Jaccard, A., Harousseau, J. L. and Bataille, R. (1998) High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. *Cancer Res.* **58**, 5640–5645
- 169 Richelda, R., Ronchetti, D., Baldini, L., Cro, L., Viggiano, L., Marzella, R., Rocchi, M., Otsuki, T., Lombardi, L., Maiolo, A. T. and Neri, A. (1997) A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. *Blood* **90**, 4062–4070
- 170 Chesi, M., Nardini, E., Brentis, L. A., Schrock, E., Ried, T., Kuehl, W. M. and Bergsagel, P. L. (1997) Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. *Nat. Genet.* **16**, 260–264
- 171 Claudio, J. O., Zhan, F., Zhuang, L., Khaja, R., Zhu, Y. X., Sivanathan, K., Trudel, S., Masih-Khan, E., Fonseca, R., Bergsagel, P. L. et al. (2007) Expression and mutation status of candidate kinases in multiple myeloma. *Leukemia* **21**, 1124–1127
- 172 Brusa, G., Zuffa, E., Hattinger, C. M., Serra, M., Remondini, D., Castellani, G., Righi, S., Campidelli, C., Pileri, S., Zinzani, P. L. et al. (2007) Genomic imbalances associated with secondary acute leukemias in Hodgkin lymphoma. *Oncol. Rep.* **18**, 1427–1434
- 173 Gutierrez, N. C., Lopez-Perez, R., Hernandez, J. M., Isidro, I., Gonzalez, B., Delgado, M., Ferriman, E., Garcia, J. L., Vazquez, L., Gonzalez, M. and San Miguel, J. F. (2005) Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. *Leukemia* **19**, 402–409
- 174 Larramendy, M. L., Niini, T., Elonen, E., Nagy, B., Ollila, J., Vihinen, M. and Knuutila, S. (2002) Overexpression of translocation-associated fusion genes of FGFR1, MYC, NPM1, and DEK, but absence of the translocations in acute myeloid leukemia. A microarray analysis. *Haematologica* **87**, 569–577
- 175 Mao, X., Onadim, Z., Price, E. A., Child, F., Lillington, D. M., Russell-Jones, R., Young, B. D. and Whittaker, S. (2003) Genomic alterations in blastic natural killer/extranodal natural killer-like T cell lymphoma with cutaneous involvement. *J. Invest. Dermatol.* **121**, 618–627
- 176 Mao, X., Orchard, G., Lillington, D. M., Russell-Jones, R., Young, B. D. and Whittaker, S. (2003) Genetic alterations in primary cutaneous CD30+ anaplastic large cell lymphoma. *Genes Chromosomes Cancer* **37**, 176–185
- 177 Mao, X., Orchard, G., Lillington, D. M., Russell-Jones, R., Young, B. D. and Whittaker, S. J. (2003) Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. *Blood* **101**, 1513–1519
- 178 Larson, A. and Cook, J. R. (2008) Fibroblast growth factor receptor 3 (FGFR3) expression in malignant lymphomas. *Appl. Immunohistochem. Mol. Morphol.* **16**, 322–325
- 179 Dvorakova, D., Krejci, P., Mayer, J., Fajkus, J., Hampl, A. and Dvorak, P. (2001) Changes in the expression of FGFR3 in patients with chronic myeloid leukaemia receiving transplants of allogeneic peripheral blood stem cells. *Br. J. Haematol.* **113**, 832–835
- 180 Dvorak, P., Dvorakova, D., Doubek, M., Faitova, J., Pacholikova, J., Hampl, A. and Mayer, J. (2003) Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia. *Leukemia* **17**, 2418–2425
- 181 Joos, S., Granzow, M., Holtgreve-Grez, H., Siebert, R., Harder, L., Martin-Subero, J. I., Wolf, J., Adamowicz, M., Barth, T. F., Lichter, P. and Jauch, A. (2003) Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. *Int. J. Cancer* **103**, 489–495
- 182 Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B. et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. *Nature* **455**, 1069–1075
- 183 Ruhe, J. E., Streit, S., Hart, S., Wong, C. H., Specht, K., Knyazev, P., Knyazeva, T., Tay, L. S., Loo, H. L., Foo, P. et al. (2007) Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. *Cancer Res.* **67**, 11368–11376
- 184 Greenman, C., Stephens, P., Smith, R., Dalgleish, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C. et al. (2007) Patterns of somatic mutation in human cancer genomes. *Nature* **446**, 153–158
- 185 Stephens, P., Edkins, S., Davies, H., Greenman, C., Cox, C., Hunter, C., Bignell, G., Teague, J., Smith, R., Stevens, C. et al. (2005) A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. *Nat. Genet.* **37**, 590–592
- 186 Lin, W. M., Baker, A. C., Beroukhir, R., Winckler, W., Feng, W., Marmion, J. M., Laine, E., Greulich, H., Tseng, H., Gates, C. et al. (2008) Modeling genomic diversity and tumor dependency in malignant melanoma. *Cancer Res.* **68**, 664–673
- 187 Davies, H., Hunter, C., Smith, R., Stephens, P., Greenman, C., Bignell, G., Teague, J., Butler, A., Edkins, S., Stevens, C. et al. (2005) Somatic mutations of the protein kinase gene family in human lung cancer. *Cancer Res.* **65**, 7591–7595
- 188 Ibrahim, O. A., Zhang, F., Eliseenkova, A. V., Linhardt, R. J. and Mohammadi, M. (2004) Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity. *Hum. Mol. Genet.* **13**, 69–78
- 189 Bardelli, A., Parsons, D. W., Silliman, N., Ptak, J., Szabo, S., Saha, S., Markowitz, S., Willson, J. K., Parmigiani, G., Kinzler, K. W. et al. (2003) Mutational analysis of the tyrosine kinome in colorectal cancers. *Science* **300**, 949
- 190 Rand, V., Huang, J., Stockwell, T., Ferriera, S., Buzko, O., Levy, S., Busam, D., Li, K., Edwards, J. B., Eberhart, C. et al. (2005) Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 14344–14349
- 191 Lew, E. D., Furdul, C. M., Anderson, K. S. and Schlessinger, J. (2009) The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations. *Sci. Signal.* **2**, ra6
- 192 Petiot, A., Ferretti, P., Copp, A. J. and Chan, C. T. (2002) Induction of chondrogenesis in neural crest cells by mutant fibroblast growth factor receptors. *Dev. Dyn.* **224**, 210–221
- 193 Gartside, M. G., Chen, H., Ibrahim, O. A., Byron, S. A., Curtis, A. V., Wellens, C. L., Bengston, A., Yudt, L. M., Eliseenkova, A. V., Ma, J. et al. (2009) Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. *Mol. Cancer Res.* **7**, 41–54
- 194 Dutt, A., Salvesen, H. B., Chen, T. H., Ramos, A. H., Onofrio, R. C., Hatton, C., Nicoletti, R., Winckler, W., Grewal, R., Hanna, M. et al. (2008) Drug-sensitive FGFR2 mutations in endometrial carcinoma. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 8713–8717
- 195 Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjoblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J. et al. (2007) The genomic landscapes of human breast and colorectal cancers. *Science* **318**, 1108–1113
- 196 Liu, T., Willmore-Payne, C., Wallander, M. L. and Layfield, L. J. (2011) Utilization of unlabeled probes for the detection of fibroblast growth factor receptor 2 exons 7 and 12 mutations in endometrial carcinoma. *Appl. Immunohistochem. Mol. Morphol.*, doi:10.1097/PAI.0b013e318201dae8
- 197 Pollock, P. M., Gartside, M. G., Dejeza, L. C., Powell, M. A., Mallon, M. A., Davies, H., Mohammadi, M., Futreal, P. A., Stratton, M. R., Trent, J. M. and Goodfellow, P. J. (2007) Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. *Oncogene* **26**, 7158–7162
- 198 Byron, S. A., Gartside, M. G., Wellens, C. L., Mallon, M. A., Keenan, J. B., Powell, M. A., Goodfellow, P. J. and Pollock, P. M. (2008) Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. *Cancer Res.* **68**, 6902–6907
- 199 Byron, S. A., Gartside, M. G., Wellens, C. L., Goodfellow, P. J., Birrer, M. J., Campbell, I. G. and Pollock, P. M. (2010) FGFR2 mutations are rare across histologic subtypes of ovarian cancer. *Gynecol. Oncol.* **117**, 125–129
- 200 Yu, K., Herr, A. B., Waksman, G. and Ornitz, D. M. (2000) Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. *Proc. Natl. Acad. Sci. U.S.A.* **97**, 14536–14541
- 201 Steinberger, D., Vriend, G., Mulliken, J. B. and Muller, U. (1998) The mutations in FGFR2-associated craniosynostoses are clustered in five structural elements of immunoglobulin-like domain III of the receptor. *Hum. Genet.* **102**, 145–150
- 202 Jang, J. H., Shin, K. H. and Park, J. G. (2001) Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. *Cancer Res.* **61**, 3541–3543
- 203 Anderson, J., Burns, H. D., Enriquez-Harris, P., Wilkie, A. O. and Heath, J. K. (1998) Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. *Hum. Mol. Genet.* **7**, 1475–1483
- 204 Robertson, S. C., Meyer, A. N., Hart, K. C., Galvin, B. D., Webster, M. K. and Donoghue, D. J. (1998) Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain. *Proc. Natl. Acad. Sci. U.S.A.* **95**, 4567–4572
- 205 Lajeunie, E., Heurtz, S., El Ghouzi, V., Martinovic, J., Renier, D., Le Merrer, M. and Bonaventure, J. (2006) Mutation screening in patients with syndromic craniosynostoses indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome. *Eur. J. Hum. Genet.* **14**, 289–298
- 206 Hansen, R. M., Goriely, A., Wall, S. A., Roberts, I. S. and Wilkie, A. O. (2005) Fibroblast growth factor receptor 2, gain-of-function mutations, and tumorigenesis: investigating a potential link. *J. Pathol.* **207**, 27–31
- 207 Rohmann, E., Brunner, H. G., Kayserili, H., Uyguner, O., Nurnberg, G., Lew, E. D., Dobbie, A., Eswarakumar, V. P., Uzumcu, A., Ulubil-Emeroglu, M. et al. (2006) Mutations in different components of FGF signaling in LADD syndrome. *Nat. Genet.* **38**, 414–417
- 208 Chen, H., Ma, J., Li, W., Eliseenkova, A. V., Xu, C., Neubert, T. A., Miller, W. T. and Mohammadi, M. (2007) A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. *Mol. Cell* **27**, 717–730
- 209 Kan, S. H., Elanko, N., Johnson, D., Cornejo-Roldan, L., Cook, J., Reich, E. W., Tomkins, S., Verloes, A., Twigg, S. R., Rannan-Eliya, S. et al. (2002) Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis. *Am. J. Hum. Genet.* **70**, 472–486

- 210 Yue, P., Forrest, W. F., Kaminker, J. S., Lohr, S., Zhang, Z. and Cavet, G. (2010) Inferring the functional effects of mutation through clusters of mutations in homologous proteins. *Hum. Mutat.* **31**, 264–271
- 211 Serizawa, R. R., Ralfkiaer, U., Steven, K., Lam, G. W., Schmiedel, S., Schuz, J., Hansen, A. B., Horn, T. and Guldberg, P. (2011) Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. *Int. J. Cancer* **129**, 78–87
- 212 Kompier, L. C., Lurkin, I., van der Aa, M. N., van Rhijn, B. W., Van der Kwast, T. H. and Zwarthoff, E. C. (2010) FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. *PLoS ONE* **5**, e13821
- 213 Zieger, K., Dyrskjot, L., Wiuf, C., Jensen, J. L., Andersen, C. L., Jensen, K. M. and Orntoft, T. F. (2005) Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. *Clin. Cancer Res.* **11**, 7709–7719
- 214 Hernandez, S., Lopez-Knowles, E., Lloreta, J., Kogevinas, M., Amoros, A., Tardon, A., Carrato, A., Serra, C., Malats, N. and Real, F. X. (2006) Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. *J. Clin. Oncol.* **24**, 3664–3671
- 215 van Oers, J. M., Lurkin, I., van Exsel, A. J., Nijsen, Y., van Rhijn, B. W., van der Aa, M. N. and Zwarthoff, E. C. (2005) A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. *Clin. Cancer Res.* **11**, 7743–7748
- 216 Hernandez, S., Lopez-Knowles, E., Lloreta, J., Kogevinas, M., Jaramillo, R., Amoros, A., Tardon, A., Garcia-Closas, R., Serra, C., Carrato, A. et al. (2005) FGFR3 and TP53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. *Clin. Cancer Res.* **11**, 5444–5450
- 217 Jebar, A. H., Hurst, C. D., Tomlinson, D. C., Johnston, C., Taylor, C. F. and Knowles, M. A. (2005) FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. *Oncogene* **24**, 5218–5225
- 218 van Rhijn, B. W., Van der Kwast, T. H., Vis, A. N., Kirkels, W. J., Boeve, E. R., Jobsis, A. C. and Zwarthoff, E. C. (2004) FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. *Cancer Res.* **64**, 1911–1914
- 219 Bakkar, A. A., Wallerand, H., Radvanyi, F., Lahaye, J. B., Pissard, S., Lecerf, L., Kouyoumdjian, J. C., Abbou, C. C., Pairon, J. C., Jaurand, M. C. et al. (2003) FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. *Cancer Res.* **63**, 8108–8112
- 220 Rieger-Christ, K. M., Mourtzinos, A., Lee, P. J., Zagha, R. M., Cain, J., Silverman, M., Libertino, J. A. and Summerhayes, I. C. (2003) Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. *Cancer* **98**, 737–744
- 221 van Rhijn, B. W., Vis, A. N., Van der Kwast, T. H., Kirkels, W. J., Radvanyi, F., Ooms, E. C., Chopin, D. K., Boeve, E. R., Jobsis, A. C. and Zwarthoff, E. C. (2003) Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. *J. Clin. Oncol.* **21**, 1912–1921
- 222 van Rhijn, B. W., Montironi, R., Zwarthoff, E. C., Jobsis, A. C. and Van der Kwast, T. H. (2002) Frequent FGFR3 mutations in urothelial papilloma. *J. Pathol.* **198**, 245–251
- 223 Kimura, T., Suzuki, H., Ohashi, T., Asano, K., Kiyota, H. and Eto, Y. (2001) The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. *Cancer* **92**, 2555–2561
- 224 Billerey, C., Chopin, D., Aubriot-Lorton, M. H., Ricol, D., Gil Diez de Medina, S., Van Rhijn, B., Bralet, M. P., Lefrere-Belda, M. A., Lahaye, J. B., Abbou, C. C. et al. (2001) Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. *Am. J. Pathol.* **158**, 1955–1959
- 225 van Rhijn, B. W., Lurkin, I., Radvanyi, F., Kirkels, W. J., Van der Kwast, T. H. and Zwarthoff, E. C. (2001) The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. *Cancer Res.* **61**, 1265–1268
- 226 Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J. P. and Radvanyi, F. (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. *Nat. Genet.* **23**, 18–20
- 227 Wallerand, H., Bakkar, A. A., de Medina, S. G., Pairon, J. C., Yang, Y. C., Vordos, D., Bittard, H., Fauconnet, S., Kouyoumdjian, J. C., Jaurand, M. C. et al. (2005) Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. *Carcinogenesis* **26**, 177–184
- 228 Chou, A., Dekker, N. and Jordan, R. C. (2009) Identification of novel fibroblast growth factor receptor 3 gene mutations in actinic cheilitis and squamous cell carcinoma of the lip. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.* **107**, 535–541
- 229 d'Avis, P. Y., Robertson, S. C., Meyer, A. N., Bardwell, W. M., Webster, M. K. and Donoghue, D. J. (1998) Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. *Cell Growth Differ.* **9**, 71–78
- 230 Sibley, K., Stern, P. and Knowles, M. A. (2001) Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. *Oncogene* **20**, 4416–4418
- 231 Wu, R., Connolly, D., Ngelangel, C., Bosch, F. X., Munoz, N. and Cho, K. R. (2000) Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix. *Oncogene* **19**, 5543–5546
- 232 Lindgren, D., Gudjonsson, S., Jee, K. J., Liedberg, F., Aits, S., Andersson, A., Chebil, G., Borg, A., Knuutila, S., Fioretos, T. et al. (2008) Recurrent and multiple bladder tumors show conserved expression profiles. *BMC Cancer* **8**, 183
- 233 Miyake, M., Sugano, K., Kawashima, K., Ichikawa, H., Hirabayashi, K., Kodama, T., Fujimoto, H., Kakizoe, T., Kanai, Y., Fujimoto, K. and Hirao, Y. (2007) Sensitive detection of FGFR3 mutations in bladder cancer and urine sediments by peptide nucleic acid-mediated real-time PCR clamping. *Biochem. Biophys. Res. Commun.* **362**, 865–871
- 234 Sibley, K., Cuthbert-Heavens, D. and Knowles, M. A. (2001) Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. *Oncogene* **20**, 686–691
- 235 Shotelersuk, V., Ittiwut, C., Shotelersuk, K., Triratanachai, S., Poovorawan, Y. and Mutirangura, A. (2001) Fibroblast growth factor receptor 3 S249C mutation in virus associated squamous cell carcinomas. *Oncol. Rep.* **8**, 1301–1304
- 236 Hernandez, S., de Muga, S., Agell, L., Juanpere, N., Esgueva, R., Lorente, J. A., Mojal, S., Serrano, S. and Lloreta, J. (2009) FGFR3 mutations in prostate cancer: association with low-grade tumors. *Mod. Pathol.* **22**, 848–856
- 237 Adar, R., Monsonogo-Ornan, E., David, P. and Yayon, A. (2002) Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization. *J. Bone Miner. Res.* **17**, 860–868
- 238 Bernard-Pierrot, I., Brams, A., Dunois-Larde, C., Caillaud, A., Gil Diez de Medina, S., Cappellen, D., Graff, G., Thiery, J. P., Chopin, D., Ricol, D. and Radvanyi, F. (2006) Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. *Carcinogenesis* **27**, 740–747
- 239 Lopez-Knowles, E., Hernandez, S., Malats, N., Kogevinas, M., Lloreta, J., Carrato, A., Tardon, A., Serra, C. and Real, F. X. (2006) PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. *Cancer Res.* **66**, 7401–7404
- 240 Ronchetti, D., Greco, A., Compasso, S., Colombo, G., Dell'Era, P., Otsuki, T., Lombardi, L. and Neri, A. (2001) Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. *Oncogene* **20**, 3553–3562
- 241 Chesi, M., Brentis, L. A., Ely, S. A., Bais, C., Robbiani, D. F., Mesri, E. A., Kuehl, W. M. and Bergsagel, P. L. (2001) Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. *Blood* **97**, 729–736
- 242 van Rhijn, B. W., van Tilborg, A. A., Lurkin, I., Bonaventure, J., de Vries, A., Thiery, J. P., Van der Kwast, T. H., Zwarthoff, E. C. and Radvanyi, F. (2002) Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. *Eur. J. Hum. Genet.* **10**, 819–824
- 243 Reddy, P. L. and Grewal, R. P. (2009) The G1138A mutation rate in the fibroblast growth factor receptor 3 (FGFR3) gene is increased in cells carrying the t(4;14) translocation. *Genet. Mol. Res.* **8**, 435–439
- 244 Naski, M. C., Wang, Q., Xu, J. and Ornitz, D. M. (1996) Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. *Nat. Genet.* **13**, 233–237
- 245 Bellus, G. A., Hefferon, T. W., Ortiz de Luna, R. I., Hecht, J. T., Horton, W. A., Machado, M., Kaitila, I., McIntosh, I. and Francomano, C. A. (1995) Achondroplasia is defined by recurrent G380R mutations of FGFR3. *Am. J. Hum. Genet.* **56**, 368–373
- 246 Fracchiolla, N. S., Luminari, S., Baldini, L., Lombardi, L., Maiolo, A. T. and Neri, A. (1998) FGFR3 gene mutations associated with human skeletal disorders occur rarely in multiple myeloma. *Blood* **92**, 2987–2989
- 247 Li, E., You, M. and Hristova, K. (2006) FGFR3 dimer stabilization due to a single amino acid pathogenic mutation. *J. Mol. Biol.* **356**, 600–612
- 248 Meyers, G. A., Orlow, S. J., Munro, I. R., Przylepa, K. A. and Jabs, E. W. (1995) Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crozon syndrome with acanthosis nigricans. *Nat. Genet.* **11**, 462–464
- 249 Parsons, D. W., Jones, S., Zhang, X., Lin, J. C., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I. M., Gallia, G. L. et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. *Science* **321**, 1807–1812
- 250 Sung, M. T., Zhang, S., Lopez-Beltran, A., Montironi, R., Wang, M., Davidson, D. D., Koch, M. O., Cain, M. P., Rink, R. C. and Cheng, L. (2009) Urothelial carcinoma following augmentation cystoplasty: an aggressive variant with distinct clinicopathological characteristics and molecular genetic alterations. *Histopathology* **55**, 161–173
- 251 Goriely, A., Hansen, R. M., Taylor, I. B., Olesen, I. A., Jacobsen, G. K., McGowan, S. J., Pfeifer, S. P., McVean, G. A., Meyts, E. R. and Wilkie, A. O. (2009) Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. *Nat. Genet.* **41**, 1247–1252
- 252 Webster, M. K., d'Avis, P. Y., Robertson, S. C. and Donoghue, D. J. (1996) Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. *Mol. Cell. Biol.* **16**, 4081–4087

- 253 Bellus, G. A., Spector, E. B., Speiser, P. W., Weaver, C. A., Garber, A. T., Bryke, C. R., Israel, J., Rosengren, S. S., Webster, M. K., Donoghue, D. J. and Francomano, C. A. (2000) Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. *Am. J. Hum. Genet.* **67**, 1411–1421
- 254 Castro-Feijoo, L., Loidi, L., Vidal, A., Parajes, S., Roson, E., Alvarez, A., Cabanas, P., Barreiro, J., Alonso, A., Dominguez, F. and Pombo, M. (2008) Hypochondroplasia and acanthosis nigricans: a new syndrome due to the p.Lys650Thr mutation in the fibroblast growth factor receptor 3 gene? *Eur. J. Endocrinol.* **159**, 243–249
- 255 Zhang, Y., Hiraishi, Y., Wang, H., Sumi, K. S., Hayashido, Y., Toratani, S., Kan, M., Sato, J. D. and Okamoto, T. (2005) Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas. *Int. J. Cancer* **117**, 166–168
- 256 Roidl, A., Foo, P., Wong, M., Mann, C., Bechtold, S., Berger, H. J., Streit, S., Ruhe, J. E., Hart, S., Ullrich, A. and Ho, H. K. (2010) The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells. *Oncogene* **29**, 1543–1552
- 257 Falvella, F. S., Frullanti, E., Galvan, A., Spinola, M., Noci, S., De Cecco, L., Nosotti, M., Santambrogio, L., Incarbone, M., Aloisio, M. et al. (2009) FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung. *Int. J. Cancer* **124**, 2880–2885
- 258 Sasaki, H., Okuda, K., Kawano, O., Yukiue, H., Yano, M. and Fujii, Y. (2008) Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer. *Oncol. Rep.* **20**, 1125–1130
- 259 Spinola, M., Leoni, V., Pignatiello, C., Conti, B., Ravagnani, F., Pastorino, U. and Dragani, T. A. (2005) Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. *J. Clin. Oncol.* **23**, 7307–7311
- 260 da Costa Andrade, V., Parise, Jr, O., Hors, C. P., de Melo Martins, P. C., Silva, A. P. and Garicochea, B. (2007) The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. *Exp. Mol. Pathol.* **82**, 53–57
- 261 Tanuma, J., Izumo, T., Hirano, M., Oyazato, Y., Hori, F., Umehara, E., Shisa, H., Hiai, H. and Kitano, M. (2010) FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma. *Oncol. Rep.* **23**, 739–744
- 262 Morimoto, Y., Ozaki, T., Ouchida, M., Umehara, N., Ohata, N., Yoshida, A., Shimizu, K. and Inoue, H. (2003) Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. *Cancer* **98**, 2245–2250
- 263 Wang, J., Stockton, D. W. and Ittmann, M. (2004) The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. *Clin. Cancer Res.* **10**, 6169–6178
- 264 Xu, B., Tong, N., Chen, S. Q., Hua, L. X., Wang, Z. J., Zhang, Z. D. and Chen, M. (2011) FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: a meta-analysis of 2618 cases and 2305 controls. *BMC Cancer* **11**, 84
- 265 Xu, W., Li, Y., Wang, X., Chen, B., Wang, Y., Liu, S., Xu, J., Zhao, W. and Wu, J. (2010) FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis including 8555 subjects. *Eur. J. Cancer* **46**, 3332–3338
- 266 Ma, Z., Tsuchiya, N., Yuasa, T., Inoue, T., Kumazawa, T., Narita, S., Horikawa, Y., Tsuruta, H., Obara, T., Saito, M. et al. (2008) Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. *Int. J. Cancer* **123**, 2574–2579
- 267 FitzGerald, L. M., Karlins, E., Karyadi, D. M., Kwon, E. M., Koopmeiners, J. S., Stanford, J. L. and Ostrander, E. A. (2009) Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis. *Prostate Cancer Prostatic Dis.* **12**, 192–197
- 268 Bange, J., Prechtel, D., Cheburkin, Y., Specht, K., Harbeck, N., Schmitt, M., Knyazeva, T., Muller, S., Gartner, S., Sures, I. et al. (2002) Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. *Cancer Res.* **62**, 840–847
- 269 Ye, Y., Shi, Y., Zhou, Y., Du, C., Wang, C., Zhan, H., Zheng, B., Cao, X., Sun, M. H. and Fu, H. (2010) The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression. *Ann. Surg. Oncol.* **17**, 3354–3361
- 270 Marks, J. L., McLellan, M. D., Zakowski, M. F., Lash, A. E., Kasai, Y., Broderick, S., Sarkaria, I. S., Pham, D., Singh, B., Miner, T. L. et al. (2007) Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. *PLoS ONE* **2**, e426
- 271 Xiao, S., Nalabolu, S. R., Aster, J. C., Ma, J., Abruzzo, L., Jaffe, E. S., Stone, R., Weissman, S. M., Hudson, T. J. and Fletcher, J. A. (1998) FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. *Nat. Genet.* **18**, 84–87
- 272 Popovici, C., Adelaide, J., Ollendorff, V., Chaffanet, M., Guasch, G., Jacrot, M., Leroux, D., Birnbaum, D. and Pebusque, M. J. (1998) Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). *Proc. Natl. Acad. Sci. U.S.A.* **95**, 5712–5717
- 273 Reiter, A., Sohal, J., Kulkarni, S., Chase, A., Macdonald, D. H., Aguiar, R. C., Goncalves, C., Hernandez, J. M., Jennings, B. A., Goldman, J. M. and Cross, N. C. (1998) Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. *Blood* **92**, 1735–1742
- 274 Smedley, D., Hamoudi, R., Clark, J., Warren, W., Abdul-Rauf, M., Somers, G., Venter, D., Fagan, K., Cooper, C. and Shipley, J. (1998) The t(8;13)(p11;q11–12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP. *Hum. Mol. Genet.* **7**, 637–642
- 275 Wong, W. S., Cheng, K. C., Lau, K. M., Chan, N. P., Shing, M. M., Cheng, S. H., Chik, K. W., Li, C. K. and Ng, M. H. (2007) Clonal evolution of 8p11 stem cell syndrome in a 14-year-old Chinese boy: a review of literature of t(8;13) associated myeloproliferative diseases. *Leuk. Res.* **31**, 235–238
- 276 Matsumoto, K., Morita, K., Takada, S., Sakura, T., Shiozaki, H., Murakami, H. and Miyawaki, S. (1999) A chronic myelogenous leukemia-like myeloproliferative disorder accompanied by T-cell lymphoblastic lymphoma with chromosome translocation t(8;13)(p11;q12): a Japanese case. *Int. J. Hematol.* **70**, 278–282
- 277 Etienne, A., Gelsi-Boyer, V., Carbuccia, N., Adelaide, J., Barba, G., La Starza, R., Murati, A., Eclache, V., Birg, F., Birnbaum, D. et al. (2007) Combined translocation with ZNF198-FGFR1 gene fusion and deletion of potential tumor suppressors in a myeloproliferative disorder. *Cancer Genet. Cytogenet.* **173**, 154–158
- 278 Demiroglu, A., Steer, E. J., Heath, C., Taylor, K., Bentley, M., Allen, S. L., Koduru, P., Brody, J. P., Hawson, G., Rodwell, R. et al. (2001) The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. *Blood* **98**, 3778–3783
- 279 Chen, J., Deangelo, D. J., Kutok, J. L., Williams, I. R., Lee, B. H., Wadleigh, M., Duclos, N., Cohen, S., Adelsperger, J., Okabe, R. et al. (2004) PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 14479–14484
- 280 Ollendorff, V., Guasch, G., Isnardon, D., Galindo, R., Birnbaum, D. and Pebusque, M. J. (1999) Characterization of FIM-FGFR1, the fusion product of the myeloproliferative disorder-associated t(8;13) translocation. *J. Biol. Chem.* **274**, 26922–26930
- 281 Roumiantsev, S., Krause, D. S., Neumann, C. A., Dimitri, C. A., Asiedu, F., Cross, N. C. and Van Etten, R. A. (2004) Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. *Cancer Cell* **5**, 287–298
- 282 Ren, M., Li, X. and Cowell, J. K. (2009) Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase. *Blood* **114**, 1576–1584
- 283 Popovici, C., Zhang, B., Gregoire, M. J., Jonveaux, P., Lafage-Pochitaloff, M., Birnbaum, D. and Pebusque, M. J. (1999) The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. *Blood* **93**, 1381–1389
- 284 Mano, Y., Takahashi, K., Ishikawa, N., Takano, A., Yasui, W., Inai, K., Nishimura, H., Tsuchiya, E., Nakamura, Y. and Daigo, Y. (2007) Fibroblast growth factor receptor 1 oncogene partner as a novel prognostic biomarker and therapeutic target for lung cancer. *Cancer Sci.* **98**, 1902–1913
- 285 Vizmanos, J. L., Hernandez, R., Vidal, M. J., Larrayoz, M. J., Otero, M. D., Marin, J., Ardanaz, M. T., Calasanz, M. J. and Cross, N. C. (2004) Clinical variability of patients with the t(6;8)(q27;p12) and FGFR10P-FGFR1 fusion: two further cases. *Hematol. J.* **5**, 534–537
- 286 Sohal, J., Chase, A., Mould, S., Corcoran, M., Oscier, D., Iqbal, S., Parker, S., Welborn, J., Harris, R. I., Martinelli, G. et al. (2001) Identification of four new translocations involving FGFR1 in myeloid disorders. *Genes Chromosomes Cancer* **32**, 155–163
- 287 Guasch, G., Ollendorff, V., Borg, J. P., Birnbaum, D. and Pebusque, M. J. (2001) 8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways. *Mol. Cell. Biol.* **21**, 8129–8142
- 288 Guasch, G., Delaval, B., Arnoulet, C., Xie, M. J., Xerri, L., Sainy, D., Birnbaum, D. and Pebusque, M. J. (2004) FOP-FGFR1 tyrosine kinase, the product of a t(6;8) translocation, induces a fatal myeloproliferative disease in mice. *Blood* **103**, 309–312
- 289 Park, T. S., Song, J., Kim, J. S., Yang, W. I., Song, S., Kim, S. J., Suh, B. and Choi, J. R. (2008) 8p11 myeloproliferative syndrome preceded by t(8;9)(p11;q33), CEP110/FGFR1 fusion transcript: morphologic, molecular, and cytogenetic characterization of myeloid neoplasms associated with eosinophilia and FGFR1 abnormality. *Cancer Genet. Cytogenet.* **181**, 93–99
- 290 Guasch, G., Mack, G. J., Popovici, C., Dastugue, N., Birnbaum, D., Rattner, J. B. and Pebusque, M. J. (2000) FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33). *Blood* **95**, 1788–1796
- 291 Yamamoto, K., Kawano, H., Nishikawa, S., Yakushijin, K., Okamura, A. and Matsui, T. (2006) A biphenotypic transformation of 8p11 myeloproliferative syndrome with CEP1/FGFR1 fusion gene. *Eur. J. Haematol.* **77**, 349–354

- 292 Mozziconacci, M. J., Carbucaia, N., Prebet, T., Charbonnier, A., Murati, A., Vey, N., Chaffanet, M. and Birnbaum, D. (2008) Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110-FGFR1 fusion: report of a new case and review of the literature. *Leuk. Res.* **32**, 1304–1308
- 293 Kim, S. Y., Oh, B., She, C. J., Kim, H. K., Jeon, Y. K., Shin, M. G., Yoon, S. S. and Lee, D. S. (2011) 8p11 myeloproliferative syndrome with BCR-FGFR1 rearrangement presenting with T-lymphoblastic lymphoma and bone marrow stromal cell proliferation: A case report and review of the literature. *Leuk. Res.* **35**, e30–e34
- 294 Agerstam, H., Lilljebjorn, H., Lassen, C., Swedin, A., Richter, J., Vandenberghe, P., Johansson, B. and Fioretos, T. (2007) Fusion gene-mediated truncation of RUNX1 as a potential mechanism underlying disease progression in the 8p11 myeloproliferative syndrome. *Genes Chromosomes Cancer* **46**, 635–643
- 295 Murati, A., Arnoulet, C., Lafage-Pochitaloff, M., Adelaide, J., Derre, M., Slama, B., Delaval, B., Popovici, C., Vey, N., Xerri, L. et al. (2005) Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion. *Int. J. Oncol.* **26**, 1485–1492
- 296 Fioretos, T., Panagopoulos, I., Lassen, C., Swedin, A., Billstrom, R., Isaksson, M., Strombeck, B., Olofsson, T., Mitelman, F. and Johansson, B. (2001) Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL. *Genes Chromosomes Cancer* **32**, 302–310
- 297 Soler, G., Nusbaum, S., Varet, B., Macintyre, E. A., Vekemans, M., Romana, S. P. and Radford-Weiss, I. (2009) LRRFIP1, a new FGFR1 partner gene associated with 8p11 myeloproliferative syndrome. *Leukemia* **23**, 1359–1361
- 298 Gu, T. L., Goss, V. L., Reeves, C., Popova, L., Nardone, J., Macneill, J., Walters, D. K., Wang, Y., Rush, J., Comb, M. J. et al. (2006) Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. *Blood* **108**, 4202–4204
- 299 Grand, E. K., Grand, F. H., Chase, A. J., Ross, F. M., Corcoran, M. M., Oscier, D. G. and Cross, N. C. (2004) Identification of a novel gene, FGFR10P2, fused to FGFR1 in 8p11 myeloproliferative syndrome. *Genes Chromosomes Cancer* **40**, 78–83
- 300 Belloni, E., Trubia, M., Gasparini, P., Micucci, C., Tapinassi, C., Confalonieri, S., Nuciforo, P., Martino, B., Lo-Coco, F., Pelicci, P. G. and Di Fiore, P. P. (2005) 8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes. *Genes Chromosomes Cancer* **42**, 320–325
- 301 Walz, C., Chase, A., Schoch, C., Weisser, A., Schlegel, F., Hochhaus, A., Fuchs, R., Schmitt-Graff, A., Hehlmann, R., Cross, N. C. and Reiter, A. (2005) The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1. *Leukemia* **19**, 1005–1009
- 302 Hidalgo-Curtis, C., Chase, A., Drachenberg, M., Roberts, M. W., Finkelstein, J. Z., Mould, S., Oscier, D., Cross, N. C. and Grand, F. H. (2008) The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre-mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1. *Genes Chromosomes Cancer* **47**, 379–385
- 303 Guasch, G., Popovici, C., Mugneret, F., Chaffanet, M., Pontarotti, P., Birnbaum, D. and Pebusque, M. J. (2003) Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3). *Blood* **101**, 286–288
- 304 Persson, F., Winnes, M., Andren, Y., Wedell, B., Dahlenfors, R., Asp, J., Mark, J., Enlund, F. and Stenman, G. (2008) High-resolution array CGH analysis of salivary gland tumors reveals fusion and amplification of the FGFR1 and PLAG1 genes in ring chromosomes. *Oncogene* **27**, 3072–3080
- 305 Wasag, B., Lierman, E., Meeus, P., Cools, J. and Vandenberghe, P. (2011) The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11). *Haematologica*, doi:10.3324/haematol.2010.036558
- 306 Yagasaki, F., Wakao, D., Yokoyama, Y., Uchida, Y., Murohashi, I., Kayano, H., Taniwaki, M., Matsuda, A. and Bessho, M. (2001) Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. *Cancer Res.* **61**, 8371–8374
- 307 Maeda, T., Yagasaki, F., Ishikawa, M., Takahashi, N. and Bessho, M. (2005) Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML. *Blood* **105**, 2115–2123

Received 4 October 2010/10 March 2011; accepted 11 March 2011  
Published on the Internet 28 June 2011, doi:10.1042/BJ20101603